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ABSTRACT 
DISORDER IN CYSTEINE-RICH GRANULIN-3 AND 
ITS IMPLICATION IN ALZHEIMER DISEASE 
 by Gaurav Ghag 
May 2017 
Granulins (GRNs) are a family of small, cysteine-rich proteins that are generated 
upon proteolytic cleavage of their precursor, progranulin (PGRN) during inflammation. 
All seven GRNs (1 – 7 or A – G) contain twelve conserved cysteines that form six 
intramolecular disulfide bonds, rendering this family of proteins unique. GRNs play 
multiple roles and are involved in a myriad of physiological as well as pathological 
processes. They are known to a play role in growth and embryonic development, wound 
healing, and signaling cascades as well as in tumorigenesis. They are also implicated in 
neurodegenerative diseases like frontotemporal dementia (FTD), Alzheimer disease 
(AD), and amyotrophic lateral sclerosis (ALS). Despite their manifold functions, there is 
a paucity in the information about the structure-function relationship of these proteins, 
especially, with the role of the twelve conserved cysteines and the disulfide linkages in 
determining their structure and the functions. In this study, the role of disulfide bonds is 
probed by comparing the structures of the fully reduced GRN-3 (rGRN-3) and native 
GRN-3. We report that monomeric rGRN-3 is an intrinsically disordered protein (IDP) at 
low concentrations and undergoes dimerization at higher concentrations to form a fuzzy 
complex. Interestingly, we show that rGRN-3 is also able to activate NF-B in human 
neuroblastoma cells in a concentration-dependent manner. We also show that both E. coli 
and mammalian HEK cells are inefficient in forming correct disulfide linkages and are 
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incapable of generating monomeric native GRN-3 (GRN-3) exclusively, thus, 
predominately generating multimeric GRN-3 (mGRN-3) with scrambled inter-molecular 
bonds. We establish that GRN-3 has a more ordered structure as compared to that of 
mGRN-3 or rGRN-3, stabilized exclusively by the disulfide bonds which form a fulcrum 
imparting order to an otherwise disordered protein. We determined the potential 
involvement of GRN-3 in AD pathogenesis by showing that GRN-3 augments Aβ, the 
protein implicated in AD, aggregation in a concentration- and time-dependent manner 
and it interacts both with Aβ monomers and oligomers thereby providing a proof of 
concept for neuroinflammation triggered neurodegeneration.  
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CHAPTER I - INTRODUCTION 
1.1 Alzheimer Disease 
1.1.1 Overview – Biochemistry and Physiology 
Alzheimer disease (AD), the most common and widely spread form of dementia, 
is a multifactorial neurodegenerative disorder characterized by the progressive 
impairment of memory, loss of cognition, altered behavior, and loss of social 
appropriateness1 As per the Alzheimer association’s 2016 report, an estimated of 5.4 
million Americans of all ages have AD and it is the fifth leading cause of death in the 
nation. The pathology primarily arises due to the progressive neuronal death in the 
cortical and hippocampal regions of the brains, which are triggered by two hallmark 
lesions called the extracellular neuritic plaques composed primarily of a protein called 
amyloid-β (Aβ), and intracellular neurofibrillary tangles (NFTs) composed primarily of 
hyperphosphorylated tau1-4 Both neuritic plaques and the neurofibrillary tangles are 
responsible for the death of the neurons, Aβ aggregates that form the major part of 
neuritic plaques are considered the prime neurotoxic agents in AD5 Aβ peptides are 
generated by a sequential proteolysis of an ubiquitously expressed, transmembrane 
precursor protein called β-amyloid precursor protein (β-APP/APP) by aspartyl proteases 
β- and γ-secretases6 γ-secretase can cleave APP at multiple positions generating several 
forms of Aβ ranging from 39 to 43 amino acids of which Aβ40 and Aβ42 are 
predominant and more prone to aggregation7 Aβ is an intrinsically disordered protein 
(IDP) and lacks a well-defined 3D structure in its monomeric state8 Like most IDPs, Aβ 
has an intrinsic propensity to aggregate into high-molecular-weight, filamentous fibrils, 
which deposit as senile plaques8, 9 The process of aggregation is nucleation-dependent 
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and displays a classic sigmoidal growth curve with an initial lag phase, followed by rapid 
growth forming soluble low molecular weight oligomers which aggregate further forming 
the soluble high molecular weight  protofibrils which undergo the processes elongation 
and lateral association to eventually form fibrils with cross β-sheet structure (Figure 
1.1)10-12  
 
Figure 1.1 Schematic representation of Aβ aggregation. 
Different species formed along the pathway. (Inset): Sigmoidal curve showing the lag-time and post-nucleation stages of aggregation. 
Though based on the classical amyloid hypothesis, fibrils are considered primarily 
responsible for the neuronal death, cognitive decline and memory impairment has been 
shown to occur even in the early stages of AD before the deposition of amyloid 
plaques.13-17 Thus, it has been shown that the low molecular weight soluble oligomers 
ranging from ~2 to 60mers are the primary neurotoxic species responsible for cognitive 
decline during early stages of AD.14, 18 Consequently, several low molecular weight 
oligomers have been identified in vivo as well as in vitro as the perpetrators of AD 
pathology.10, 19 Due to their increased significance in disease pathology, characterization 
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of structure-function relationships of these low molecular weight soluble oligomers is 
warranted to discern their precise role in disease progression. However, it is difficult to 
isolate and generate in vivo oligomers from physiological samples in adequate amounts to 
characterize them biophysically. Thus, considerable focus has been on generating and 
isolating exogenous oligomers that mimic the physiological ones.20-22 Recently, our lab 
has generated and isolated in vitro oligomers called LFAOs (large fatty acid derived 
oligomers) in the presence of fatty acid interfaces.23 LFAOs have been shown to undergo 
unique self-propagative replication by quantitatively converting more monomers into 
similar toxic oligomers.24, 25 Moreover, these LFAOs (12-24mers) undergo prototypical 
prion-like propagation to form LFAO strain-specific fibrils via a three-step mechanism.26 
1.1.2 Neuroinflammation as One of the Perpetrators of AD 
Most cases of AD are idiopathic while some are familial and can be attributed to 
the rare autosomal dominant mutations in the genes for APP and presenilin (protein 
involved in processing of APP to Aβ).27 However, the precise etiology of the disease is 
unknown and the complex nature of the disease makes it difficult to point out any single 
perpetrator of the disease. One of the predominant events that is observed in AD brains is 
the chronic activation of the innate immune responses and neuroinflammatory 
cascades.28, 29 Deposition of Aβ plaques as well the soluble toxic oligomers of Aβ have 
been shown to activate microglia and astrocytes in the affected brains leading to the 
release of an array of proinflammatory neurotoxins like cytokines like tumor necrosis 
factor (TNF)-α, interleukin (IL)-6, interferon (IFN)-γ, etc., chemokines, reactive oxygen 
and nitrogen species, complement proteins and other proinflammatory proteins, and 
several proteolytic enzymes.30, 31 In contrast, the activation of microglia upon an 
 4 
inflammatory event is the key defense mechanism of the innate immune system of the 
brain32, and activated microglia also facilitate in clearing the amyloid plaque load via 
endocytosis.33-35 However, chronic activation of these microglial cells in AD causes them 
to get arrested in proinflammatory state thus impeding their neuroprotective phagocytic 
role.36 Thus, neuroinflammation is one of the important drivers of the disease progression 
exacerbating neuronal loss. However, activation of inflammatory pathways before or 
during the disease onset may also account for as the cause of the disease. In this respect, 
few evidences corroborate the causative role of inflammation. Biochemical investigation 
and immunohistochemical studies have shown surge in the release of cytokines like IL-1, 
IL-6, and TNFα and other inflammatory proteins at the onset of AD37, and clinical 
investigations have shown that individuals with prolonged use of non-steroidal anti-
inflammatory drugs (NSAIDs) are at reduced risk of developing AD.38, 39 Moreover, 
inflammation triggered by external factors like a traumatic brain injury such chronic 
concussions during contact sports or in war veterans, severe viral infections of the CNS, 
metabolic stress associated with other disease like diabetes, or even severe emotional 
stress due to life altering events also increase the risk of developing late-onset AD.40-43 
The arrest of microglia in the proinflammatory diseased state and the studies that 
show dysfunctional clearance of amyloid plaques by diseased microglia34, 44 warrant the 
systematic investigation of the molecular processes that occur as the downstream effect 
of such a condition and their role in the disease onset as well as progression, specifically, 
with respect to myriads of proinflammatory mediators released from activated microglia 
and their interaction with Aβ. It is well-documented that the chemically-activated 
microglia secrete several proinflammatory mediators that stimulate APP production and 
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its processing to Aβ peptides.45, 46 Thus, these proinflammatory mediators could play a 
crucial role in the onset as well as the progression of AD by directly interacting with Aβ 
thereby modulating its aggregation leading to the formation of toxic 
aggregates/oligomers. These Aβ aggregates can, in turn, further activate more microglial 
cells causing release of more proinflammatory mediators thereby drastically increasing 
their local concentrations in CNS. This will further exacerbate the diseased state leading 
to a self-perpetuating and self-amplifying cyclical pathway as depicted schematically in 
Figure 1.2. 
 
Figure 1.2 Role of neuroinflammation triggered by TBI in AD pathogenesis 
Of all the proinflammatory mediators implicated in AD onset, this research 
focuses on a family of unique proinflammatory proteins called Granulins, specifically 
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Granulin-B. These proteins have been already implicated in other neurodegenerative 
diseases like frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) as 
well in AD. The ensuing sections detail the structure-function relationship of Granulins, 
specifically, Granulin 3 also referred as Granulin-Β and elaborate their implications in 
AD and other neurodegenerative diseases. 
1.2 Progranulin and Granulins – Overview 
1.2.1 Progranulin 
Progranulin (PGRN) or granulin-epithelin precursor, proepithelin, PC-cell derived 
growth factor, and acrogranulin is a 68.5 kDa secretory growth factor with pleiotropic 
roles in physiological as well as pathological processes.47-51 The gene for PGRN is 
located on chromosome 17q21.32 in humans52 and chromosome 11 in mouse.53 PGRN is 
highly conserved in plants, insects, worms, fish, and mammals including humans.54-57 
Moreover, PGRN is expressed ubiquitously throughout the human body including the 
epithelial cells of intestinal crypt, skin, and reproductive organs58, 59, immune system 
organs like spleen and lymph nodes and in the innate immune system cells59, and in 
central nervous system both in the neurons and the neuroinflammatory cells like 
microglia.60-62 The expression of PGRN is well distributed in the neurons in the different 
regions like the neocortex, hippocampus, Purkinje cells of the cerebellum, and in the 
motor neurons.59-62 However, more recently the augmented secretion of PGRN from the 
microglial cells activated due to an external or internal traumatic injury or insult to the 
brain have come to bear significance with respect to the neuroinflammatory role of 
PGRN and GRNs in neurodegenerative diseases like Alzheimer disease and Parkinson’s 
disease.63 In this context, several reports have shown an increased secretion of PGRNs 
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and GRNs from the activated microglia in mouse models of spinal cord injury64, 65, 
traumatic brain injury66, Alzheimer disease63, and multiple sclerosis.67 
PGRN is a heavily glycosylated protein68 with 593 amino acids and consists of 
seven and a half tandem repeats of cysteine-rich motifs (1 – 7 and P) called Granulins 
(GRNs) or Epithelins (Figure 1.3).47, 49, 52, 69, 70 Each of the seven GRN motifs consists of 
twelve conserved cysteines that form six intra-molecular disulfide bonds as indicated for 
GRN-3 in Figure 1.3.71 The GRN motifs are released by the proteolytic digestion of 
PGRN by an array of proteases like neutrophil elastase72, proteinase 3 (a neutrophil 
protease)73, MMP-12 (matrix metalloproteinase 12; macrophage elastase)74, MMP-1475, 
and ADAMTS-7 (a disintegrin and metalloproteinase with thrombospondin motifs)76 
during an inflammatory event by cleaving in the linker regions between the GRN 
domains.72 The cleavage sites have been mapped for all the GRNs to the linker regions 
except for GRNs 2, 3, and 4.72 
 
Figure 1.3 The domain structure of PGRN. 
The numbers/letters in the boxes represent the granulins (1 – 7 or A – G & P) and amino acid sequence of GRN-3 is shown below with 
conserved cysteines in red and putative disulfide bonds.77 The scissors represent the sites at which the proteases cleave PGRN, asterisk 
represents that the sites have not been identified yet. 
1.2.2 Granulins 
Granulins (GRNs) or epithelins were first isolated from the human inflammatory 
cells extracts and from the rat bone marrow.69 Initially, individual GRNs were isolated 
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from several sources and molecular cloning and northern blot analysis showed that the 
GRNs were expressed as a precursor protein called PGRN by a single gene.49 Four of the 
seven GRNs, GRNs A or 4, Β or 3, C or 5, and D or 6 were isolated from the human 
leukocyte granule extract69, whereas the fifth GRN, GRN-F or 2 was isolated from 
urine.78 All seven GRNs (GRNs 1 – 7) are about ~6 kDa in size and all, but GRN-1 or 
GRN-G, are characterized by presence of twelve conserved cysteines; four pairs towards 
the center of the protein flanked by two single cysteines at both N- and C-termini; GRN-1 
has only 10 conserved cysteines.49, 52 These cysteines from six intra-molecular disulfide 
bonds with a putative interlocking pattern depicted in Figure 1.3. Microsequencing of 
full-length human and rat GRN-4 (GRN-A), purified from bone marrow extracts, 
confirmed that the two proteins are highly homologous as well as partial N-terminal 
sequencing of GRNs 3 (GRN-B), 5 (GRN-C), and 6 (GRN-D) confirmed that they are 
closely related to human GRN-4.79 In fact, the sequence comparison of all seven GRNs 
from humans reveals 37 – 60% homology as depicted in Figure 1.4. Perhaps, the 
evolutionarily conserved cysteines residues among all the GRNs play a significant role in 
determining the structure and function of the proteins. 
 
Figure 1.4 The sequence alignment of human GRNs. 
The conserved amino acid residues are highlighted and the sequence in the box is the consensus sequence. Dashes have been 
introduced to align the cysteines. 
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1.3 Structure and Functions of Progranulin and Granulins 
1.3.1 Progranulin 
Most of the research in the past has been focused on understanding the functions 
of PGRN but not much is known about the structure of PGRN except for its domain 
architecture, which is depicted in Figure 1.3 and elaborated in section 1.2.1. The 
functions of PGRN can be categorized as growth-factor-like activities, immune 
modulation, and neurotrophic effects. Additionally, PGRN has been implicated in the 
progression of tumor in the brain as well as in the periphery80 and has been implicated in 
neurodegenerative diseases like Frontotemporal Dementia (FTD), Alzheimer Disease 
(AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS).81 The 
detailed role of PGRN and GRNs in neurodegenerative diseases like FTD and AD will be 
discussed later (see section 1.4). The growth-factor-like activities of PGRN are 
manifested as early as during embryonic development; PGRN has been detected in both 
male and female reproductive cells.59, 82, 83 A glycoprotein called acrogranulin present in 
the acrosomes of guinea pig sperms has been found to be guinea pig equivalent of PGRN 
based on structural characterization.47, 84 The expression of PGRN is highest in the 
trophectodermal cells of the blastocysts84, which form the fetal compartment of the 
placenta. They are the first lineage that are committed to become epithelial cell line 
reiterating the growth-factor-like role played by PGRN in epithelia. Needless to say, 
PGRN is a growth-factor for trophectodermal cells promoting cavitation and blastocoel 
expansion, indispensable steps during development of the zygote.82 Moreover, post-
implantation expression of PGRN has been shown to be critical for the prenatal sexual 
differentiation of the rat brains85, thus reinforcing the trophic role of PGRN in CNS as 
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early as during embryonic development. The trophic effects of PGRN in neurons are 
characterized by their ability to promote survival of cortical and motor neurons86 and 
neurite outgrowth87, in culture. Additionally, PGRN functions as chemoattractant for 
microglia and stimulate the endocytosis of Αβ peptides implicated in Alzheimer disease88 
and also protects the brain against deposition of Αβ peptides.89 
The role of PGRN in tissue repair and inflammation, both in periphery and in the 
brain, is complex. After an injury, human and murine skin show an elevated expression 
of PGRN in wound fibroblasts and endothelial cells which remained elevated above the 
baseline for at least 10 days after the injury.90 Several inflammatory cells expressed 
PGRN at higher levels as they get wounded.90 Extraneous application of PGRN to 
cutaneous wounds in rats has shown to increase the accumulation of blood vessels and 
fibroblasts in the wound.90 More significantly, increasing evidence implicate a critical 
role of PGRN in neuroinflammation. As stated before, PGRN is mainly expressed in 
activated microglia62 in response to trauma such as spinal cord injury65 or axotomy.60 
Moreover, the elevated expression of PGRN is observed in activated microglia in FTD 
and AD.63 PGRN is known to bind to the receptors for the tumor necrosis factor α (TNF-
α)91 and inhibit the downstream TNF-α signal transduction.72 PGRN also inhibits the 
ability of TNF-α to promote spreading and degranulation of neutrophils and their 
respiratory bursts.72, 73 Thus, PGRN is known to have anti-inflammatory activities. This 
activity is enhanced in the presence of secretory leukocyte protease inhibitor (SLPI) 
which functions to protect the proteolysis of PGRN into individual GRN peptides by 
serine proteases.72 This is significant as activated microglia that secrete PGRN, also 
secrete the several proteases that cleave PGRN and without the SLPI protein, PGRN is 
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prone to get cleaved into GRN peptides that, interestingly, have opposite activities as 
detailed in the next section (see 1.3.2).72 Thus, in an inflamed environment, the ratio of 
intact anti-inflammatory PGRN to the proinflammatory GRN peptides is determined by 
the ratio of SLPI and elastases which could play a critical role in determining the role of 
PGRN/GRNs in neuroinflammatory pathways involved in neurodegenerative diseases. 
1.3.2 Granulins 
Even though there is not much sequence homology between GRNs and other 
growth factors, similarities between the tertiary structure of mammalian GRNs and that 
of epithelial cell-specific transforming growth factor (TGFe) are quite striking.79 
Additionally, GRNs have structural subdomains that closely resemble – 1) the cysteine-
rich epidermal growth factor (EGF) like domains, that contain six cysteines that form 
three disulfide bonds, present in epidermal growth factor (EGF), and transforming growth 
factor-α (TGFα; Figure 1.5A).92-94, and the kringle domains, which are disordered 
domains stabilized by six disulfide bonds, present in several proteins like the hepatocyte 
growth factor95, 96, proteases involved in blood clotting such as prothrombin, and 
plasminogen97, apolipoprotein98, and tissue plasminogen activator99. The secondary 
structure of carp-GRN 1 (cGRN1) and human GRNs 4, 5, and 2 has been solved using 
2D-NMR.71, 100 The 2D-NMR structure of cGRN1 revealed a unique structure of 4 
stacked β-hairpins stabilized by six intra-hairpins (intra-molecular) disulfide bonds with 
the peptide backbone forming a left-handed helix giving an overall twisted ladder-like 
structure (Figure 1.5B). Similarly, there of the seven human GRNs, GRNs 4, 5, and 2 
were shown to form the N-terminal stack of β-hairpins with the cross-linked disulfide 
bonds as observed for the N-terminal region of cGRN1.71, 100, 101 Out of the two N-
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terminal β-hairpins, the second was found to be most stable as a single amino acid 
substitutions did not alter its stability.100 The C-terminal domain, on the contrary, was 
found to be disordered.100 
 
Figure 1.5 Structural domain comparison of GRN-4. 
Α, Comparison of Grn domain and murine EGF domain showing the structural overlap; Β, The MOLSCRIPT representation of the 
cGrn1 structure showing the unique fold with four stacked β-hairpins connected by six disulfide bonds.71 
In fact, only 28 of the 57 residues of cGRN1 were found to be part of the β-hairpins fold, 
whereas the rest of the residues were unstructured71 and this analysis can be extended to 
human GRNs as well as only N-terminal was shown to have well-defined structure. The 
structure of the rest of the human GRNs could not be elucidated as they were either a 
heterogeneous mixture of several disulfide bond isoforms or completely lacked 
structure.100 For instance, purified GRN6 consisted of two molecular species and yielded 
confusing NMR spectra, whereas GRN-3, GRN-7, and GRN-1 completely lacked any 
structure.100 Furthermore, it is not known if GRN-3 and GRN-7 attained any stable 
structure within PGRN.100 Thus, though the N-terminal domain of human GRN4, 5, and 2 
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was found to be similar to that of cGRN1, all having a well-defined stacked β-hairpin 
structure, there is still ambiguity about the structure of other GRNs, and so is the 
uncertainty about the disulfide pairing.100 It is noteworthy that several hydrophobic and 
turn stabilizing amino acid residues present in cGRN1 are absent in human GRNs, which 
could contribute to the plasticity and disorderness observed among the latter.100, 102 
Nevertheless, human GRNs have been implicated in several physiological and 
pathological processes although it remains uncertain if these multiple functions are 
mediated by individual GRNs or PGRN or both. The lack of clear knowledge about the 
functions of GRNs has been exacerbated by the difficulty in obtaining the proteins in 
homogenous forms in vitro due to the difficulty posed by the high degree of disulfide 
bonds in the protein. Despite these difficulties, some studies have revealed important 
roles human GRNs take part in. GRN-6 was shown to be mitogenic for glioma cells, 
although its structure was only partially characterized.103 GRN-3 was found to inhibit the 
growth and proliferation of epithelial cells lines, A549 and SW-13 while inducing 
excessive amount of interleukine-8 (IL-8) secretion72 Both GRN-4 and GRN-3 could not 
inhibit the TNFα induced respiratory burst and the release of proteinases by neutrophils.72 
These studies establish that GRN-3 is proinflammatory, which and implicate a 
proinflammatory nature of GRN-4. 
1.4 Implications in Neurodegenerative Disorders 
1.4.1 PGRN and GRNs in AD 
As mentioned in section 1.1.2, mediators released by activated microglia arrested 
in the diseased proinflammatory state may play a crucial role in the onset and the 
progression of AD pathology. Cytokines have been shown to overexpress in AD and are 
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known to trigger plaque formation and neuronal degradation.104 PGRNs and GRNs could 
play a critical role in this regard by directly interaction with Aβ and triggering its 
aggregation. PGRNs and GRNs been implicated in other neurodegenerative diseases like 
FTD (detailed in section 1.4.2) and ALS. Indeed, several polymorphisms of PGRN have 
been linked to sporadic AD and haplotypes have been identified that contribute to the 
increased risk of AD.105, 106 PGRN and GRNs have also found to colocalize with Aβ 
plaques at postmortem examinations of brains of the patients with AD.88 In another study, 
similar results were observed in a transgenic mouse model of AD.107 Moreover, the 
activated microglial cells that are associated with the Aβ plaques63 over-express PGRN as 
well as the proteolytic enzymes that cleave PGRN into proinflammatory GRNs.108  This 
increased expression in microglia may play a pivotal role in the response to brain injury, 
neuroinflammation, and neurodegeneration. Though PGRN is anti-inflammatory and has 
neuroprotective role, the precise roles of the proinflammatory GRNs remain elusive. 
1.4.2 Involvement in Frontotemporal Dementia (FTD) 
Frontotemporal dementia is the second most common form of presenile dementia 
after AD and accounts for 5-10 % of all dementia.109 The clinical manifestations in FTD 
include abnormalities of personality, behavior and/or prominent language impairment, 
such as progressive non-fluent aphasia or semantic dementia.110 Certain severe patients 
also exhibit traits of Parkinson’s disease or motor neuron disease (MND).111 FTD 
involves prominent neuronal loss and atrophy of the frontal and temporal lobes.109 The 
pathology of the disease varies with few cases showing hyperphosphorylated tau and α-
synuclein (α-syn) positive aggregates in neurons and gliomas112, whereas a majority of 
cases of FTD show neuritis or neuronal cytoplasmic inclusions (NCI) in superficial layers 
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of the neocortex and hippocampus that are immunoreactive for ubiquitin but not for tau 
or α-syn.113, 114 Interestingly, FTD patients show familial inheritance in 20-50% cases and 
the most common pattern of inheritance is autosomal dominant.115-117 Mutations in 
PGRN, located on chromosome 17q21 in humans resulting in null alleles, were shown to 
be one of the main causes of familial form of FTD81 with a frequency of 5-10% among 
all familial cases.87, 118 The pathology in these cases include the accumulation of 
ubiquitinated TDP-43 (Tar DNA binding protein) aggregates in the frontal and temporal 
cortices81, 119, 120. These null mutations in PGRN result in the premature transcription 
termination and formation of immature mRNAs, which get degraded by the process of 
nonsense-mediated decay (NMD).81 This results in a condition called haploinsufficiency 
resulting in lower than normal level of PGRN in CSF, blood, and in unaffected regions of 
the brain.121-124 However, the exact molecular mechanisms that link haploinsufficiency of 
PGRN to ubiquitin-positive TDP-43 inclusions in FTD are not known. Interestingly, 
TDP-43 accumulation is also seen in other neurodegenerative diseases like non-PGRN 
FTD, ALS, and AD.125 In addition to the null mutations that lead to haploinsufficiency of 
PGRN, a few missense mutations, mapped to be present in GRN-3 sequence of PGRN, 
have also been implicated in FTD126, 127. However, if these mutations alter the structure of 
GRN-3 and/or PGRN is not known but molecular modeling studies have indicated that 
the P43L mutation in the GRN-3 sequence can have a destabilizing effect on the putative 
β-hairpin structure of GRN-3.126 The discovery of the mutations in the PGRN involved in 
FTD and its loss of function thereof led to the hypothesis that restoring the normal levels 
of PGRN could serve as an excellent therapeutic strategy. Indeed, several studies have 
shown that the effects of PGRN deficiency could be rescued by heterologous expression 
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of PGRN.87, 128, 129 This corroborates the proposed theory that restoring PGRN expression 
could reverse the effects caused by its deficiency and serve as a potential therapy in FTD. 
1.5 Rationale for the Study 
One of the remarkable characteristics of PGRN and its cleaved peptides, GRNs, is 
that they are involved in multiple biological processes. As elaborated in the previous 
sections (see sections 1.2 and 1.3), both PGRN and GRNs play crucial roles in plethora 
of physiological as well as pathological functions. Addition to this list is their role in 
tumorigenesis and cancer development.90 However, even though PGRN and/or GRNs are 
involved in myriads of processes, the overarching question about the precise roles played 
by the precursor protein, PGRN and those by the peptide products, GRNs, especially in 
central nervous system (CNS) is still unanswered. Clearly, PGRN and GRNs have 
opposite cellular activities: while PGRN is known to be anti-inflammatory and has been 
shown to be neuroprotective and support neuronal growth86, 87, GRNs are predicted to be 
proinflammatory, especially GRN-3.72 
Several clinical evidences point towards critical roles of GRNs in AD (detailed in 
section 1.4.1). However, the underlying reasons for the multifunctional roles of GRNs are 
not known. However, one could explain the reason for multifunctional roles by the 
potential structural plasticity that will allow GRNs to interact with multiple partners 
culminating in numerous biological activities. Such a plasticity is a well-known trait of 
intrinsically disordered proteins (IDPs), which lack a well-defined 3D structure in their 
native state, exhibit structural malleability.130 Perhaps, the observed lack of structure for 
GRN-3, GRN7, and GRN1 and the disordered C-termini in GRNs 4, 2, and 5100 could 
account for certain degree of intrinsic disorder among GRNs and thus explain the 
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multifunctional roles associated with them. Additionally, according to the 2D-NMR 
structure of GRN4, 31 of the 58 residues were found to be unstructured.100 However, 
further detailed structural-function studies are warranted to corroborate this claim 
especially with respect to understanding the role played by the disulfide bonds in 
dictating the structure and hence functions of GRNs. This research aims at understanding 
the structure-function relationship of one of the seven GRNs, GRN-3. The rationale 
behind choosing GRN-3 is: 
1. Two of missense mutations implicated in FTD are in GRN-3 sequence126 and 
2. It is the only GRN for which direct experimental evidence for pro-
inflammatory nature exists.72 
The overarching hypothesis of this study is that disulfide bonds play a critical 
role in determining the structure of GRN-3 with potential implications on its multitude 
of functions, especially with respect to its role in neurodegenerative diseases. The broad 
questions that are being asked here are: 
1. Is there a disorder within the structure of GRN-3 and what is the precise role 
of disulfide bonds in dictating this structural stability and/or plasticity? 
2. What is the role of GRN-3 in AD? Does GRN-3 interact with A peptide to 
modulate the latter’s aggregation and neuronal toxicity? 
The ensuing chapters attempt to answer these questions. In Chapter II, we 
investigate the role of disulfide bonds in the structure of GRN-3, first by completely 
abrogating the disulfide bonds (section 2.2), and second by studying the structure-
function of GRN-3 with intra- as well as intermolecular disulfide bonds (section 2.5). In 
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Chapter III, we investigate the molecular interactions GRN-3 with Aβ to discern its role 
in Aβ aggregation and consequently AD pathogenesis. 
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CHAPTER II - ROLE OF DISULFIDE BONDS IN GRN-3 
2.1 Hypothesis and Rationale 
Disulfide bonds play an important role in determining the structure and the 
function of proteins, especially the secretory proteins that function in the extracellular 
matrix.131 They are known to impart stability by decreasing the conformational entropy of 
the unfolded proteins.132 Additionally, they maintain the integrity of the proteins by 
inducing structural rigidity thereby protecting them against the oxidants and proteolytic 
enzymes in the extracellular matrix.131 The role of disulfide bonds in fostering structural 
rigidity has been studies in several globular proteins133-136, antibodies137-139, and growth 
factors containing the cysteine-rich kringle domains.95, 140 Though rigid in nature, 
disulfide bonds can undergo cleavages/exchanges in secretory proteins like 
thrombospondin-1, plasmin, CD4, etc. in order to assist in their functions131, 141-143. 
Furthermore, disulfide bonds play an important role in maintaining homeostasis during 
oxidative stress, one example being glutathione.144 
Granulins are highly cysteine-rich, secretory proteins each forming six intra-
molecular disulfide bonds (12 cysteines). Moreover, the cysteines are highly conserved in 
all the seven GRNs (Figure 1.4) possibly forming same disulfide linkages as predicted for 
GRN4 based on its NMR structure.100 These evidences advocate a critical role of 
disulfide bonds in dictating the structure and possibly the functions of GRNs. We 
hypothesize that the structure of GRN-3 is mainly dictated by the six intra-molecular 
bonds. 
 
 
 20 
2.2 Investigations on Fully Reduced GRN-3 (rGRN-3) 
The role of the twelve conserved cysteines in determining the structure and 
perhaps the function of GRN-3 was determined by studying the effect of loss of disulfide 
bonds on its structure and functions. The following sections detail the results obtained by 
investigating rGRN-3. 
2.3 Results 
2.3.1 In silico Analysis Reveals rGRN-3 to be Disordered 
As disulfide bonds are known to facilitate structural stability and rigidity in 
proteins, abrogating them completely can potentially render the protein unstructured. 
Therefore, to test whether rGRN-3 is disordered, we employed in silico prediction 
software called Predictor of Naturally Disordered Regions (PONDR) (www.pondr.com). 
PONDR uses several prediction algorithms such as VLXT145, VLS2B146, VL3147, and a 
meta-predictor called PONDR-Fit148 to compute the disorder propensity of amino acids 
assigning a disorder disposition score to proteins. Each of these tools assign the disorder 
score by employing artificial neural networks trained on different datasets.148 PONDR 
VLXT uses three neural networks, one each for the terminal regions of the proteins and 
one for the internal region, trained on datasets of X-ray and NMR-derived protein 
structures. However, the shortcoming of PONDR VLXT is that it may be incapable of 
predicting long disordered segments in the proteins.148 PONDR VL3 uses ten neural 
networks that are trained using sequence profiles and can accurately predict longer 
disordered sequences by majority voting. PONDR VLS2B uses neural networks that can 
accurately predict both short and long disordered sequences and are trained on sequence 
profiles as well as sequence alignments from PSI-BLAST (position-specific iterated 
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BLAST) and secondary structure predictors PHD and PSI-pred.146 As mentioned earlier, 
PONDR Fit is a meta-predictor and is constructed by combining the prediction 
algorithms of other meta-predictors like PONDR VLXT, PONDR VLS2, and PONDT 
VL3 along with other predictors like FoldIndex, IUPred, and TopID.148 PONDR analyses 
of rGRN-3 revealed that rGRN-3 is completely disordered according to VLS2B and VL3 
prediction with a disorder disposition score of >0.6 (Figure 2.1B, blue and red lines) 
whereas PONDR Fit and VLXT predicted that only 60 and 30% of rGRN-3 is disordered 
with a disorder disposition score of >0.5, respectively (Figure 2.1B, green and grey lines). 
Thus, PONDR analyses of rGRN-3 showed disparity in the predictions. This disparity 
could arise due to following reasons: 
1. PONDR VLXT uses a training data set consisted of only 15 cysteine-
containing proteins and the cysteine content in these protein is very low (0.5-
20%) that are present both in reduced and oxidized form.145 This makes it less 
accurate in predicting the disordered disposition of GRN-3 with cysteine 
content of nearly 20% 
2. VL3 and VLS2B could be more accurate in predicting disordered disposition 
of rGRN-3 than VLXT as they are more accurate in predicting larger 
disordered regions with >30 amino acids 
Therefore, to test if the disparity in prediction is due to the presence of twelve 
cysteines in rGRN-3, same tools were used to predict the disorder disposition of GRN-3 
with cysteines replaced with alanine (alaGRN-3) and serine (serGRN-3). As expected, 
both VLXT and PONDR Fit, as well as VL3 and VSL2B, predicted disorder for more 
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than 90% of the protein sequence with a disorder disposition of >0.5 (Figures 2.1C and 
D). 
 
Figure 2.1 In silico analysis of intrinsic disorder of rGRN-3, alaGRN-3, and serGRN-3. 
A Primary sequence of rGRN-3. The * at position 28 indicates the Y to W substitution made to facilitate spectroscopic analyses. B, C, 
and D, PONDR (predictor of naturally disordered regions) analyses of rGRN-3, alaGRN-3, and serGRN-3, respectively using VLXT 
(grey), VSL2B (blue), VL3 (red) and PONDR-Fit (green) predictors. E, CIDER analysis of rGRN-3, alaGRN-3, and serGRN-3 using 
the diagram of states (plot of positively charged residues vs. fraction of negatively charged residues). CIDER analyses compute low a 
low kappa (κ) value of 0.214, low FCR (fraction of charged residues) value of 0.167, and disorder-promoting value of 0.6 for rGRN-3 
and 0.8 for alaGRN-3 and serGRN-3, respectively. 
Though cysteines are considered to be order-promoting amino acids, the disparity 
observed in case of rGRN-3 indicates the lack of attributes of the amino acid (oxidized 
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vs. reduced) in disorder predicting software. Further, rGRN-3 and the alaGRN-3 and 
serGRN-3 were analyzed using another bioinformatic tool called CIDER or Classification 
of Intrinsically Disordered Ensemble Region149 and found that rGRN-3 as well as 
alaGRN-3 and serGRN-3 (Figure 2.1E, black dot) fall in the region 1 (Figure 2.1E, light 
green) of the diagram of states (plot of fraction of positively charged residues vs. the 
fraction of negatively charged residues) indicating that the proteins are weak 
polyampholytes or polyelectrolytes with globular random coils. Aβ42, an IDP implicated 
in AD, also falls in the same region (data not shown). Based on the CIDER analyses, the 
κ value (indicator of charged amino acid mixing within a sequence) and FCR (fraction of 
charged residue) value for rGRN-3, alaGRN-3, and serGRN-3 were 0.214 and 0.167, 
respectively (Figure 2.1E, Table). Additionally, the disorder-promoting score as per 
CIDER analyses for rGRN-3 was 0.6 while that for ala- and serGRN-3 was 0.8 further 
implicating that rGRN-3 and its ala and ser mutants are unstructured. 
2.3.2 rGRN-3 Shows Potential to Dimerize via Non-Covalent Interactions 
In order to facilitate spectroscopic characterization of rGRN-3, a Y24W 
substitution was introduced in the sequence (Figure 2.1A, *). This substitution can be 
considered inert and will probably not alter the native structure of GRN-3 as W is 
conserved at this position in all GRNs except for GRN-3 and GRN-1. This Y24WGRN-3, 
denoted as rGRN-3, was expressed recombinantly in E. coli SHuffleTM cells (NEB labs) 
as a thioredoxin fusion protein as both the thioredoxin tag and the SHuffle cells promote 
disulfide bond formation in the cytoplasm. The overall purification strategy to yield 
rGRN-3 has been summarized in Figure 2.2. Briefly, after Ni2+-NTA affinity purification 
of trxA-GRN-3, it was reduced with molar excess of TCEP-HCl (Tris (2-carboxyethyl)  
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Figure 2.2 Schematic of rGRN-3 Purification. 
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phosphine hydrochloride) which is a strong reducing agent and reduces all the disulfide 
bonds. The reduced eluate was diluted to 10-20 times in volume using appropriate buffer 
and dialyzed to gradually remove imidazole and TCEP. However, surprisingly, even after 
dialyzing TCEP, the protein remained reduced for 5-6 h at room temperature (described 
in detail later in the chapter). The concentration of the protein was estimated 
spectrophotometrically using the calculated molar extinction coefficient of 6250 M-1cm-1 
at 280 nm150. HPLC fractionation of thrombin-cleaved thioredoxin fused rGRN-3 
resulted in the elution of rGRN-3 in fractions 10 and 11 (Figure 2.3A, arrow). The other 
peak seen on the HPLC profile is of thioredoxin. rGRN-3 when analyzed using SDS-
PAGE under reducing and non-reducing conditions revealed a single band at about ~6.3 
kDa under both the conditions (Figure 2.4B, lanes 1 and 2) corresponding to the 
monomeric rGRN-3 as the monoisotopic mass of monomeric rGRN-3 is 6367.39 Da as 
computed using the Compute PI/Mw tool at expasy.org. The MALDI-ToF analysis of 
purified rGRN-3 showed a major peak at an m/z value of 6367.72 Da corresponding to its 
monomeric molecular weight. Further, when analyzed using SDS-PAGE without the heat 
treatment under non-reducing condition, a diffuse band was observed at around ~13 kDa, 
corresponding to the dimeric mass of rGRN-3, in addition to monomeric rGRN-3 (Figure 
2.4B; lane 3). Since, the proteins electrophorese as a single monomeric band under 
reducing and non-reducing conditions formation of intermolecular disulfide bonds can be 
ruled out, implicating that the dimerization must be predominantly due to non-covalent 
interactions. In support of this claim, indeed, a peak at m/z of 12735.3 Da corresponding 
to dimeric rGRN-3 was also observed in MALDI-ToF spectrum (Figure 2.4C).  
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Figure 2.3 Characterization of Recombinant rGRN-3. 
Α, HPLC profile of rGRN-3 purification after thrombin cleavage. The peak marked with an arrow indicates the fraction corresponding 
to the rGRN-3. The other peak is of thioredoxin. Β, SDS-PAGE analysis of the rGRN-3 fraction marked with an arrow on the HPLC 
profile. Lane 1 is rGRN-3 reduced using 2-mercaptoethanol (β-ME) and boiled; Lane 2 is non-reduced and boiled rGRN-3 sample; 
Lane 3 is non-reduced and not boiled rGRN-3 sample. C, MALDI-ToF analysis of rGRN-3 indicating a m/z of 6367.39 Da, 
corresponding to monomeric mass (theoretical MW 6367.4 Da) and a second peak with m/z of 12735.7 Da corresponding to dimeric 
rGRN-3. D, Alkylation of rGRN-3 with iodoacetamide, showing a signal at 6993.7 Da indicating presence of 10.7 (~11) free thiols 
(reduced cysteines). The results are representative of three or more consistent repeats. 
In order to confirm that the protein is indeed reduced, Ellman’s assay and alkylation 
using iodoacetamide were carried out. Ellman’s assay performed on freshly purified 
rGRN-3 samples indicated >95% of the cysteines were in the reduced form. Further 
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iodoacetamide alkylation unambiguously confirmed that the protein was indeed reduced, 
as the treatment yielded a single peak with m/z value of 6993.7 equivalent to 10.7 (~11) 
cysteines being present as free sulfhydryls (Figure 2.3D). Thus, the percentage of free 
cysteines as calculated using Ellman’s results was in good agreement with those obtained 
via alkylation confirming that over 90% of the rGRN-3 was present in a reduced form. In 
order to assess the extent of re-oxidation of disulfide bonds, Ellman’s assay was 
performed on rGRN-3 sample incubate at room temperature for 6 h, the timeframe within 
which most of the experiments were performed. The assay revealed that 95 % of 
cysteines remained reduced within the timeframe (Figure 2.4A).  
 
Figure 2.4 Re-oxidation of rGRN-3. 
Α, Ellman’s assay results on potential re-oxidation of rGRN-3 within the experimental window and after incubation for 7 days at 4 °C. 
Β, rGRN-3 was alkylated using iodoacetamide after incubation at 4 °C for 20 days, showing a signal corresponding to 6774.8 Da 
indicating presence of seven free sulfhydryls. 
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Furthermore, even after incubation of the protein up to 7 days at 4 °C showed no change 
in oxidation content based on the Ellman’s analysis (Figure 2.4A). Only after 20 days at 4 
°C, four out of twelve cysteines of rGRN-3 re-oxidized based on iodoacetamide 
alkylation (Figure 2.4B). 
2.3.3 rGRN-3 is Intrinsically Disordered at Low Concentrations 
Several experimental evidences were gathered to validate the disordered structure 
of rGRN-3 as predicted by PONDR analysis. The secondary structure of rGRN-3 at 
different protein concentrations was analyzed using far-UV circular dichroism (CD) 
spectroscopy. rGRN-3 was observed to be predominantly disordered between 
concentrations of 10 and 100 μM as indicated by the canonical random coil CD spectrum 
exhibiting a minimum at  = 200 nm observed for disordered proteins (Figure 2.5A). 
Concentrations below 10 µM also exhibited random coil structure (Figure 2.6A). The 
degree of disorder was inversely proportional to protein concentration as the rGRN-3 
concentration increased above 100 μM, a decrease in the ellipticity at 200 nm (indicative 
of random coil) and a consequent increase in negative ellipticity at 222 nm, indicative of 
-helical structure was observed (Figure 2.5A). This inverse proportionality became 
more distinct at concentration 300 μM and above, exhibiting a distinct negative ellipticity 
at 225 nm (Figure 2.5A; inset) suggesting a transformation towards -helical structure 
(222 nm) with contributions from turns and loops (230 nm). The spectra above 800 M 
indicated a sharp negative minimum at 230 nm, suggesting presence of loops and turns, 
however, the spectrum was partly obscured by fluctuations associated with high voltage 
at low wavelengths (Figure 2.6B). When subjected to zonal fractionation by size 
exclusion chromatography (SEC), rGRN-3 eluted at fractions three times higher than its  
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Figure 2.5 rGRN-3 is an IDP. 
Α, Concentration-dependent conformational changes in rGRN-3 observed by far-UV CD. (Inset) Spectra as a difference in the molar 
ellipticities at 222 nm (helix) and 200 nm (random coil). B, Fractionation of rGRN-3 using a SuperdexTM 75 size exclusion column 
(solid line) compared to that of gel filtration standards (dotted line) – 1-bovine thyroglobulin (670 kDa), 2-bovine γ-globulin (158 
kDa), 3-chicken ovalbumin (44 kDa), 4-horse myoglobin (17 kDa), and 5-vitamin B12 (1.35 kDa). C, 
1H-15N SoFast HMQC NMR 
spectrum of rGRN-3. 
monomeric molecular weight when compared to the globular protein standards (BioRad) 
(Figure 2.5B, dotted line). Several IDPs typically exhibit a 2-3 fold increase in molecular 
weight during SEC fractionation due to the increased hydration sphere around the 
unfolded structure151 further confirming the disordered structure of rGRN-3. To obtain 
unambiguous evidence for the disordered structure of rGRN-3, 1H-15N HMQC NMR was 
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performed. In 1H-15N HMQC, the resonances of the backbone amide nitrogen of each 
residue (with the exception of prolines) can be correlated to the resonance of amide 
protons and the amide bonds along with the side chain amide nitrogens give signals.152 
The 1H-15N HMQC spectrum of rGRN-3 showed lack of dispersion for the resonances on 
the proton dimension; most of the proton resonances were seen between 8.0 and 8.5 ppm 
for 1H, however, the resonances were well-dispersed between 104 and 128 ppm on 15N 
(Figure 2.5C). This difference in the spectral dispersion in the proton and nitrogen 
dimensions is indicative of structural disorder.152 Moreover, most of the resonances in the 
proton dimension were overlapping and showed significant line broadening confirming 
that rGRN-3 is an IDP. 
 
Figure 2.6 Far-UV CD spectra of rGRN-3 at low and high concentrations. 
Α, 1 μM (dashed line) and 5 μM (continuous line), and Β, 860 μM. 
To further confirm the intrinsic disorder of rGRN-3, the effect of osmolytes like 
trifluoroethanol (TFE) and trimethylamine N-oxide (TMAO) on the structure of rGRN-3 
was assessed. TFE is a known α-helix inducer while TMAO facilitates formation of 
folded structures in proteins.153 The far-UV CD spectra of rGRN-3 obtained in the 
presence of increasing concentrations of TFE showed that TFE induced α-helical 
 31 
conformation within rGRN-3 at concentrations as low as 20-30% TFE (Figure 2.7A). The 
mid-point of this transition (equivalent to the melting point during protein unfolding) was 
low, ~16 ± 5% TFE (Figure 2.7A, inset), which provides further evidence that rGRN-3 is 
intrinsically disordered as typically disordered proteins tend to have low transition mid-
point. Similarly, TMAO also induced significant conformational changes in rGRN-3 
(Figure 2.7B). As the TMAO concentrations increased, significant loss of random coil 
structure was observed (decrease in negative minimum at 198 nm) and at higher 
concentrations, a negative minimum at around 216 nm and a positive maximum at 198nm 
were observed, indicative of β-sheet conformation (Figure 2.7B). These changes were 
predominantly observed at 198 nm where the negative minimum became a positive 
maximum with increasing TMAO concentrations. Collectively, these results indicate that 
rGRN-3 is an intrinsically disordered protein as predicted by in silico analyses. 
 
Figure 2.7 Effect of osmolytes on rGRN-3 structure. 
Α, Far UV CD spectra of rGRN-3 in the presence of increasing concentrations of TFE. (Inset) The difference in the ellipticities 
between 208 and 222 nm (helix) plotted against the percentage of TFE. The data was fitted with Boltzmann’s sigmoidal equation to 
obtain a melting concentration of 16 ± 5% TFE. B, Far UV CD spectra of rGRN-3 in presence of increasing concentrations of 
trimethylamine N-oxide (TMAO). 
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2.3.4 rGRN-3 Dimerizes to Form a Fuzzy Complex 
The SDS-PAGE analysis of rGRN-3 under non-reducing condition without the 
heat treatment alluded to the fact that rGRN-3 forms non-covalent dimers (Figure 2.3B). 
To obtain further evidence that rGRN-3 dimerizes via non-covalent interactions, 
electrophoretic, spectroscopic, and sedimentation analyses were performed. The 
electrophoresis of 100 μM rGRN-3 under non-denaturing and non-reducing conditions 
using a 25 mM Tris running buffer, pH 8.8 revealed a diffuse band corresponding to 
dimeric (D; 12.6 kDa) as well as monomeric (M; 6.3 kDa) (Figure 2.8A; inset). The 
electrophoresis of Aβ42 under identical conditions yielded three distinct bands 
corresponding to monomer (M; 4.5 kDa), dimer (D; 9 kDa), and trimer (T; 13.5 kDa) 
(Figure 2.8A; inset). Both rGRN-3 and Aβ42 have very similar pIs; 5.33 and 5.31, 
respectively, and hence their electrophoretic mobility is comparable provided all the other 
conditions are maintain constant. Further, sedimentation velocity analysis of rGRN-3 
again at 100 µM by analytical ultracentrifugation (AUC) showed two peaks; a major peak 
at 1.5 S, which was deconvoluted to 13.1 kDa corresponding to dimeric rGRN-3 and a 
minor peak at 0.4 S, which was deconvoluted to 4.5 kDa, indicative of monomeric rGRN-
3 (Figure 2.8A). Dimerization was also probed spectroscopically using ANS and 
tryptophan fluorescence. ANS or 8-anilino naphthalene sulfonic acid binds specifically to 
solvent-exposed hydrophobic surfaces on proteins. In the ANS fluorescence assay, the 
concentration of rGRN-3 was varied from 1 to 25 μM keeping the ANS concentration 
constant at 500 µM (Figure 2.8B; inset). When the normalized ANS fluorescence 
emission, monitored at 512 nm, was plotted against rGRN-3 concentration, an  
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Figure 2.8 Dimerization of rGRN-3. 
Α, Molecular size distribution of rGRN-3 at 100 μM obtained by sedimentation velocity indicates a predominant dimer (MW 13.1 
kDa). (Inset) Native PAGE analysis of rGRN-3 at 100 μM run on a 14% gel indicates a diffuse dimeric band corresponding to ~13 
kDa, based on the Aβ sample electrophoresed in parallel for which monomer (M; 4.5 kDa), dimer (D; 9.0 kDa), and trimer (T; 13.5 
kDa) are observed. B, and D, rGRN-3 () concentration-dependent ANS binding and intrinsic tryptophan fluorescence, respectively. 
The normalized fluorescence was plotted against protein concentration, and data was fitted (solid line) to a monomer-dimer model as 
described in SI. Bovine serum albumin (BSA) () was used as a negative control. (Inset) B, Representative normalized ANS 
fluorescence scans of 25 μM and 1 μM rGRN-3. C, Representative normalized tryptophan fluorescence scans of 25 μM and 1 μM 
rGRN-3. E, Normalized Stern-Volmer plots for 10 () and 100 () μM rGRN-3 using acrylamide as the quenching agent. 
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exponential decay curve was obtained with increasing rGRN-3 concentration (Figure 
2.8B; ). This exponential decrease with increasing concentration suggested that lower 
concentrations of rGRN-3 contain more solvent-exposed hydrophobic binding surfaces 
and as the concentration increased, the available hydrophobic surfaces for ANS binding 
decreased, likely due to the involvement of these hydrophobic surfaces in dimerization, 
rendering them unavailable to ANS to bind. The normalized data was fitted to the 
following monomer-dimer model: 
𝐹 =
2
𝑀
∗ {𝐹0 − (𝐹0 − 𝐹𝑓 ) ∗ (
(4𝑀 +  𝐾𝑑) ± √(4𝑀 +  𝐾𝑑)2 − 16𝑀2 
8
)} 
Based on this model, an apparent dissociation constant, 𝐾𝑑
𝑎𝑝𝑝
 of 0.24 ± 0.02 μM was 
calculated. As a negative control, ANS binding to BSA, which is known to undergo weak 
dimerization was monitored. BSA showed an increase in normalized ANS fluorescence 
intensity with an increase in protein concentration (Figure 2.8B; ). In addition to ANS 
fluorescence, the intrinsic fluorescence emission arising from solvent exposure of the 
single tryptophan residue (Y24W) within rGRN-3 was monitored as a function of protein 
concentration. The protein was serially diluted using 20 mM Tris, pH 6.5, containing 
0.01% NaN3 and the W fluorescence was monitored for each dilution. At low rGRN-3 
concentrations, the λmax for tryptophan emission was observed at 355 nm which is 
typical for a solvent exposed W residue in an IDP. At high rGRN-3 concentration, a 
slight blue shift (to 352 nm) in the λmax of W residue was observed (Figure 2.8C), 
indicative of a small change in the hydrophobic environment around the tryptophan 
residue possibly due to dimerization. Further, the normalized fluorescence showed an 
exponential increase with increasing rGRN-3 concentration (Figure 2.8D; ), suggesting 
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a distinct conformational change around the tryptophan residue, similar to that observed 
previously for human interferon γ.154 Fitting the data with the same monomer-dimer 
model as used in case of ANS binding, yielded an apparent 𝐾𝑑
𝑎𝑝𝑝
 of 0.9 ± 0.17 μM, 
comparable to the value obtained from ANS binding data. Again BSA, as a negative 
control, showed relatively weak transitions in normalized fluorescence intensity, 
indicating very weak dimerization (Figure 2.8D; ). To provide further evidence to 
support conformation changes occurring around the tryptophan reside due dimerization of 
rGRN-3, solvent accessibility of tryptophan at low and high rGRN-3 concentrations was 
investigated by Stern-Volmer analysis.155 The assay involved monitoring the tryptophan 
fluorescence in the presence of increasing concentration of a fluorescence quencher like 
acrylamide. A significant deviation from linearity was observed at both low (10 M, 
Figure 2.8E; ) and high concentrations (100 M, Figure 2.8E; ). The upward 
curvature of the fluorescence intensities was indicative of both static and dynamic 
quenching mechanisms due to tryptophan being solvent exposed. Further, the deviation 
of the normalized fluorescence intensity was more distinct at lower rGRN-3 concertation 
as compared to higher rGRN-3 concentrations indicating that the tryptophan is more 
solvent exposed at lower concentration when the protein is monomeric as against at 
higher concentration when rGRN-3 is predominantly dimeric. The quenching 
experiments at concentrations below 10 µM could not be performed as intensities 
dropped below detection limits. However, since 10 and 100 µM rGRN-3 would contain 
significant monomer and dimer populations, respectively, the data provides a reliable 
insight into solvent exposure surrounding the tryptophan residue. 
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The secondary structure and the NMR analyses of rGRN-3 indicate that rGRN-3 
exists as an IDP within the concentration range of 10-100 µM (Figure 2.5A and C), 
concentration at which is exhibits monomer-dimer dynamic. Thus, rGRN-3 associates to 
form dimers without a net gain in the overall structure. Typically, when IDPs self-
associate or associate with their binding partner, they undergo a disorder to order 
transition. However, an increasing number of IDPs have been shown to self-associate 
without undergoing disorder to order transition; they remain disordered and form fuzzy 
complexes.156 157-160 Thus, rGRN-3 forms a fuzzy complex containing intrinsically 
disordered, homogenous dimers. Collectively, these data indicate that rGRN-3 displays 
following concentration-dependent changes: 
1. < 1 μM – intrinsically disordered, monomeric, 
2. 50-100 μM - intrinsically disordered, dimeric, and 
3. 300 μM – partially α-helical/turns. 
2.3.5 Low Concentrations of rGRN-3 Activate NF-B in SH-SY5Y Human 
Neuroblastoma Cells 
Native GRN-3 has been shown to be pro-inflammatory.72 However, several 
secretory proteins that are rich in disulfide bonds undergo disulfide cleavages or 
exchanges to perform their functions.131 Though rare, rGRN-3 can likely be present in 
rare circumstances such as cellular stress or during the breakdown of protein folding 
machinery and may elicit inflammatory response. Therefore, the ability of rGRN-3 to 
activate NF-Β a generic marker for neuroinflammation, was assessed in SY-SH5Y 
human neuroblastoma cells. These experiments were conducted by our collaborator, Dr. 
Melissa Moss’s lab at the University of South Carolina. In this assay, the 
 37 
immunocytochemistry was coupled with an antibody specific for an epitope that is 
accessible on the p65 or RelA subunit of NF-B only when NF-B is present in an 
unbound state. When NF-B is bound to inhibitor of B (IB), it remains inactive in the 
cytoplasm. An inflammatory stimulus will trigger the phosphorylation, ubiquitination, 
and degradation of IB and subsequent release of NF-B leading to its activation and 
nuclear translocation.161-163 Thus, the primary antibody employed in these 
immunocytochemistry studies is specific for the activated form of NF-B. 
 
Figure 2.9 Effect of rGRN-3 on NF-κB activation in SH-SY5Y cells. 
SH-SY5Y cells were incubated alone (control, A – C) or in the presence of 0.02 (D – F), 0.2 (G – I), 0.5 (J – L), 0.8 (not shown), 1 
(not shown), or 2 μM (M – O) rGRN-3. Immunofluorescence staining was performed for the activated form of NF-κB (red) in 
conjunction with nuclear DAPI (blue) staining. Scale bars = 50 μm. Inserts located in top left corners represent 1.5x magnification. P, 
Activated NF-κB staining intensity per cell was analyzed using a custom MATLAB routine as described in the Experimental 
Procedures. Results are reported relative to the control. Error bars indicate SEM, n = 3-4. *p < 0.05, relative to the control. 
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SH-SY5Y cells treated with the negative control displayed low NF-B activation 
(Figure 2.9A-C). When cells were exposed for 60 minutes to medium containing 0.02 
M rGRN-3, a slight increase in NF-B activation was observed (Figure 2.9D-F). 
However, image analysis employed to quantify activated NF-B staining per cell 
revealed that this increase did not reach significance (Figure 2.9P).  In contrast, SH-
SY5Y cells treated with medium containing 0.2 M or 0.5 M rGRN-3 demonstrated a 
significant increase in NF-B activation when compared to the control (Figure 2.9G-L, 
P). Thus, at rGRN-3 concentrations of 0.5 M or lower, a dose-dependent increase in 
rGRN-3 activation of NF-B was observed. Treatment of SH-SY5Y cells with higher 
rGRN-3 concentrations of 0.8 M, 1 M, and 2 M (Figure 2.9M-O, P), however, failed 
to elicit any increase in NF-B activation. This latter result indicates that the dose-
dependent increase in rGRN-3 activation of NF-B does not extend to concentrations 0.8 
M and above. 
2.4 Discussion and Conclusions 
The objective of this study was to determine the role of the six intra-molecular 
disulfide bonds in dictating the structure of GRN-3 by studying the effect of the 
abrogation of these disulfide bonds on GRN-3 structure. The advantage of this approach 
over making cysteines mutants is that any changes in the structure would primarily be 
due the removal of disulfide bonds and not due introduction of other amino acids in the 
primary sequence. However, the challenge with this approach is to maintain the cysteines 
in the reduced form as sulfhydryls can inherently oxidize to form disulfide linkages. The 
purification strategy adopted yielded reduced GRN-3 that was resistant to spontaneous 
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oxidation in the timeframe of all the experiments as shown by Ellman’s and alkylation 
results (Refer section 2.5.2; Figure 2.4). 
This study established that rGRN-3 is an IDP at low concentrations, as predicted 
by the PONDR and CIDER analyses. This results suggests that abrogation of disulfide 
bonds renders the protein unstructured and that these disulfide linkages are the sole 
driving force dictating the structure of the protein. This finding is significant as it answers 
the overarching question regarding the role of disulfide linkages in determining the 
structure of GRNs and can be extrapolated to all the other six GRNs as the cysteines and 
putatively even the disulfide bonding pattern is conserved among all the GRNs. 
Interestingly, the intrinsically disordered rGRN-3 exhibits concentration-dependent 
structural changes and exists as non-covalent dimers at higher concentrations. Moreover, 
it dimerizes without any gain in the secondary structure forming fuzzy complexes, a 
characteristic exhibited by an increasing number of IDPs.159, 164 Thus, the results obtained 
in this study implicate that the structure of native, oxidized GRN-3 is predominantly 
dictated by the six intra-molecular disulfide bonds and not the inherent property of amino 
acids to form secondary and tertiary structures. 
Interestingly, removal of disulfide bonds doesn’t affect the pro-inflammatory 
nature of GRN-3 as the data presented shows that rGRN-3 is capable of activating NF-
κB, a generic pro-inflammatory marker, in a dose-dependent manner in the SH-SY5Y 
human neuroblastoma cells. Moreover, the NF-κB activation is attenuated at higher 
concentration indicating that monomeric rGRN-3 has higher pro-inflammatory activity as 
compared to dimeric rGRN-3. The concentration (0.5 – 0.8 μM) at which rGRN-3 
maximally activates NF- κB overlaps with the monomer-dimer dynamics of rGRN-3 and 
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is in close agreement with the apparent dissociation constant (𝐾𝑑
𝑎𝑝𝑝
) for rGRN-3 
dimerization (0.2-0.9 µM). Although, physiologically this pro-inflammatory nature of 
rGRN-3 may not hold much relevance but in certain rare situations such as metabolic or 
oxidative stress or during breakdown of folding machinery, GRN-3 may undergo 
disulfide cleavage and exists in the reduced form. Moreover, since rGRN-3 is an IDP that 
are evolutionary adapted to have pleiotropic functions165, the presence of rGRN-3 in the 
extracellular matrix may be physiologically relevant in certain conditions. 
Thus, the overall conclusions from this study are that rGRN-3 is an IDP at low 
concentrations implicating that the disulfide bonds are the sole driving force for 
maintaining the structure of GRN-3. Investigating the structure-function relationship of 
the native GRN-3 is, therefore, imperative to finding evidence in support of our 
hypothesis I. The ensuing sections will provide answers to these questions. 
2.5 Investigations on Native GRN-3 
The abrogation of the disulfide bonds in GRN-3 renders the protein disordered, as 
detailed in the previous chapter. These results corroborate with the proposed hypothesis 
that the reduction of the disulfide bonds results in complete loss of structure of GRN-3 
and implicates that the disulfide bonds could be the main driver for the structural integrity 
of GRN-3. However, rGRN-3 provides an indirect evidence for the role of disulfide 
bonds in driving the structure of GRN-3. Therefore, to understand the role of played by 
disulfide bonds in dictating the structure of GRN-3 and its functions, it is imperative to 
characterize the structure and the function of the native GRN-3 with completely oxidized 
six intra-molecular disulfide bonds. The subsequent sections present the biophysical and 
biochemical characterization of the native GRN-3. 
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2.6 Results 
2.6.1 Recombinant Expression of GRN-3 in E. coli Show Significant Disulfide Bond 
Scrambled Multimers 
GRN-3 was expressed recombinantly in E. coli SHuffleTM cells (NEB, Ipswich, 
MA) as a thioredoxin fusion protein (GRN-3-trxA) as previously reported166. This fusion 
construct and cells were chosen for two distinct advantages: SHuffleTM  cells are 
engineered to constitutively express protein disulfide bond isomerase (DsbC) in the 
cytoplasm which facilitates the correct disulfide bond formation and prevents disulfide 
bond scrambling167 and the cells also carry the knockout mutations of the thioredoxin and 
glutathione reductase genes (ΔtrxB, Δgor) which help maintain an oxidative environment 
in the cytoplasm conducive to disulfide bond formation. Furthermore, to facilitate the 
spectroscopic characterization of GRN-3, a Y24W substitution was introduced in the 
sequence (Figure 2.10A). This substitution is conservative as all GRNs except GRN-3 
and GRN-1 have a conserved Y at this position. After nickel affinity purification and 
thioredoxin cleavage by thrombin, GRN-3 was fractionated using a C18 reverse phase 
HPLC column. The sample fractionated in multiple fractions between 47 to 68, which 
indicates the presence of many isoforms in the protein (Figure 2.10B, dashed box, and 
Figure 2.10C). The cleaved thioredoxin (trxA) eluted at later fractions at ~90. Distinct 
and some well-resolved peaks were observed for fractions between 47 to 68 (Figure 
2.10C). To confirm the purity, the molecular mass and disulfide bond integrity of the 
protein in the fractions between 47 and 68, SDS-PAGE analysis was conducted under 
both reducing and non-reducing conditions. As expected, a single band at about 6.3 kDa  
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Figure 2.10 Characterization of GRN-3. 
Α, Primary amino acid sequence of GRN-3 with putative disulfide bonding pattern. The * represents the Y28W mutation. B, HPLC 
fractionation of GRN-3 after thrombin cleavage. The peaks corresponding to the different disulfide bond isoforms of GRN-3 are 
marked with a dashed box. C, Zoomed image of the different disulfide bond GRN-3 isoforms showing distinctly resolved isoforms. 
Two of the fractions have been labeled for representation purposes. This HPLC profile is representative of three or more consistent 
repeats. D, SDS-PAGE analysis of the HPLC fractions 47 to 65, 67, & 68 under reducing (βME +) and non-reducing (βME -) 
conditions. The numbers indicated below the gels are the corresponding fraction numbers. Of all the fractions, fraction 48 shows a 
single band under reducing and non-reducing conditions corresponding to the GRN-3 monomer (Mw = 6.3 kDa) whereas fraction 56 
shows a single band corresponding to GRN-3 monomeric and bands corresponding to the GRN-3 monomer, dimer, and trimer. E, & F, 
MALDI-ToF spectra of fractions 48 showing a predominant signal corresponding to GRN-3 monomer (M) and a relatively minor peak 
corresponding to the dimer (D) and fraction 56 showing signals corresponding to the monomer (M), dimer (D), trimer (T), tetramer 
(Te), and Pentamer (P). 
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was observed under reducing conditions in all the fractions corresponding to the average 
mass of monomeric GRN-3 (Figure 2.10D, lanes β-ME +). In addition to monomeric 
band, bands corresponding to dimeric (~12.7 kDa) and/or trimeric (~19.1 kDa) GRN-3 
were also observed for all the fractions, expect for fraction 48, under non-reducing 
condition (Figure 2.10D, lanes β-ME -), indicating that these fractions primarily contain 
intermolecularly disulfide-bonded multimers. Fraction 48 is the only one that indicated 
monomeric protein containing intra-molecular disulfide bonds. Although a faint smear 
could be observed for fraction 48 under non-reducing condition, the percentage of a 
dimer is negligible as compared to the other fractions. MALDI-ToF mass spectrometric 
analysis of fraction 48 showed a predominant signal at m/z value of 6355.65 Da (M), 
which corresponds to the molecular weight of monomeric GRN-3 along with a relatively 
minor signal corresponding to dimeric GRN-3 (D) indicating presence of less than 10% 
of dimeric GRN-3 (Figure 2.10E). In contrast, the mass spectrum of fraction 56 showed 
signals at m/z values of corresponding to monomer or 6356.52 Da (M) along with those 
corresponding to a dimer (D), trimer (T), tetramer (Te), and a pentamer (P) (Figure 
2.10F). Similar multimeric peaks were observed in all the fractions between 49 and 68 
(Figure 2.11A). To further confirm the integrity of disulfide bonds, Ellman’s assay and 
alkylation assay using iodoacetamide were performed. Freshly purified GRN-3 and 
mGRN-3 samples indicated that <5% of the cysteines were in the reduced form, 
respectively, by Ellman’s assay. The iodoacetamide alkylation confirmed that only 1 – 2 
cysteines were present as free sulfhydryls (Figure 2.11B). Fraction 56 was chosen as 
mGRN-3 for further analyses as it showed highest concentration among all other  
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Figure 2.11 MALDI-ToF of fractions 47-68 and Alkylation of Fractions 48 and 56. 
Α, MALDI-ToF spectra of fractions 47 to 68 (other than 48 and 56) showing multimers. Β, Iodoacetamide alkylation of fraction 48 
and 56 showing ~1 free sulfhydryls each indicating presence of one free cysteine. 
multimeric fractions. Thus, from the SDS-PAGE and MALDI-ToF analyses, it was 
apparent that the native GRN-3 elutes exclusively at fraction 48. Quantitation of fraction 
48 as compared to overall GRN-3 expression between fractions 47 to 68 showed that the 
monomer only accounted for 5% of the total protein expressed. Despite the presence of 
thioredoxin and oxidized environment provided by the SHuffleTM cells, E. coli seems to 
be incapable of generating correct disulfide bonded protein, likely due to the high 
cysteine content as well as the placement of cysteines (multiple adjacent positions) in 
GRN-3 (Figure 2.10A). 
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2.6.2 GRN-3 Expressed in Human Embryonic Kidney (HEK) Cells Also Form 
Multimers with Intermolecular Disulfide Bonds. 
We reasoned that the inability of E. coli to express GRN-3 with correct intra-
molecular disulfide bonds could be due to the ineffectiveness of rudimentary post-
translational processing machinery in E. coli that is incapable of generating correct 
disulfide bonds for a protein with high cysteine content. Therefore, to address this, GRN-
3 was expressed and purified from human embryonic kidney (HEK) cells to assess if the 
mammalian post-translational machinery will assist in the formation of intramolecularly 
disulfide bonded, monomeric GRN-3. Expression and the purification of GRN-3 from 
HEK cells, referred to as hGRN-3 henceforth was performed in our collaborator, Dr. 
Thomas Kukar’s lab at Emory university. hGRN-3 was subjected to SDS-PAGE and 
MALDI-ToF analyses similar to those generated in E. coli. SDS-PAGE, under reducing 
conditions, showed a distinct band at ~ 12 kDa corresponding to monomeric hGRN-3 
along with a smear between 15 and 20 kDa (Figure 2.12A, lane 1). The smear may reflect 
the glycosylated form of the protein. In the absence of heat treatment, the sample did not 
show much change in the banding pattern suggesting the bands observed arise due to 
covalent interactions, that is, inter-molecular disulfide bonds (Figure 2.12A, lane 3). 
hGRN-3 sample electrophoresed under non-reducing conditions both with and without 
heat treatment largely showed a faint band corresponding to monomeric (single arrow), 
predominant band corresponding to dimeric (double arrow), and another faint band 
corresponding to trimeric (triple arrow) hGRN-3, which was absent in the reduced 
samples (Figure 2.12A, lanes 2 and 4). Thus, the SDS-PAGE analysis suggests that  
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Figure 2.12 Characterization of hGRN-3 expressed and purified from human embryonic 
kidney (HEK) cells. 
Α, SDS-PAGE of hGRN-3 under reduced and non-reduced and boiled (lanes 1 and 2, respectively) and reduced and non-reduced and 
not boiled (lanes 3 and 4, respectively). The presence of monomer, dimers, and trimers in lanes 2 are marked with single, double, and 
triple arrows, respectively. Β, MALDI-ToF spectra of hGRN-3 showing signals corresponding to monomeric hGRN-3 (single arrow), 
dimeric hGRN-3 (double arrows), and trimeric hGRN-3 (triple arrows and that of reduced hGRN-3 showing predominant signal 
corresponding to monomeric hGRN-3 (single arrow) and a relatively minor peak corresponding to dimeric hGRN-3 (double arrows). 
The results are indicative of three consistent repeats. 
hGRN-3 forms multimers arising from intermolecular disulfide bonds. Similarly, the 
MALDI-ToF spectrum of hGRN-3 under reducing conditions showed the presence of a 
predominant monomeric peak (Figure 2.12B, single arrow) along with a relatively minor 
dimeric peak (Figure 2.12B, double arrow). In contrast, under non-reducing conditions, 
distinct signals corresponding to dimers (Figure 2.12B, double arrow) and trimers (Figure 
2.12B, triple arrow) in addition to the monomeric signal (Figure 2.12B, single arrow) 
were observed. The possibility of multimers arising from non-covalent interactions is 
eliminated by the presence of identical banding pattern between heat-treated and 
untreated samples. These data unambiguously indicate that hGRN-3 expressed in 
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mammalian cells also forms multimers with inter-molecular disulfide bonds. Thus, these 
results along with the results from expression in E. coli show that irrespective of cell 
type, the post-translational machinery seems to inefficient in generating homogenous 
disulfide bonds in GRN-3. The only thing that may vary between GRN-3 from E. coli 
and hGRN-3 from HEK cells is the extent of multimers present. Since the GRN-3 
expressed and purified from the HEK cells was largely similar to that from E. coli, and 
due to the limitation in the amount of protein produced in HEK cells for biophysical 
analyses, E. coli expressed protein was used primarily for further analyses. 
2.6.3 GRN-3 is More Ordered than mGRN-3 and rGRN-3 
To discern the role of disulfide bonds in determining the structure of GRN-3, we 
used 1H-15N heteronuclear multiple quantum coherence (HMQC) NMR and CD 
spectroscopy to probe the structure of GRN-3 and compared it with that of mGRN-3 and 
rGRN-3. The HMQC spectrum of GRN-3 showed well-resolved resonances with good 
spectral dispersion between 6.8 & 9.5 ppm and 104 & 130 ppm on the 1H dimension and 
15N dimensions, respectively (Figure 2.13A, GRN-3). The resonances for all the 
backbone amides and side chain amide nitrogens, except for the 6 proline residues, 
present in the GRN-3 sequence (Figure 2.10A) could be accounted. The broad signals 
observed at 7.4 and 7.8 ppm on the 1H scale and at 104 and 109 ppm on the 15N scale, 
respectively can potentially be attributed to the two arginine and lysine residues.168-170 
The peaks at 7.0 and 129 ppm are negative peaks arising from potential contaminants. 
The well spread-out spectral dispersion in both the proton and the nitrogen dimensions 
indicate a well-defined structure for GRN-3 and though the HMQC data is not sufficient 
to discern its structure, the overall spectrum resembles that of a β-sheet containing  
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protein. The spectrum of mGRN-3, on the other hand, was less dispersed as compared to 
that of GRN-3 in the proton dimension, however, majority of the residues displayed well-
resolved resonances (Figure 2.13A, mGRN-3). Nevertheless, some overlapping 
resonances were observed between 8 and 8.5 ppm suggesting that mGRN-3 has a partly 
folded structure with certain parts resembling a collapsed molten globule containing the 
hydrophobic residues. Perhaps, the scrambling of disulfide bonds forming intermolecular 
links causes the protein to resemble a molten globule type structure. The NMR results of 
GRN-3 and mGRN-3 and those of rGRN-3, which is completely disordered (detailed in 
section 2.2.3), indicate that disulfide bonds play a crucial and major part in determining 
the structure of GRN-3. 
To further bolster the NMR data the samples were analyzed by far-UV CD 
spectroscopy. Surprisingly, the far-UV circular dichroism (CD) spectroscopy of GRN-3 
showed the protein to be largely disordered as indicated by the canonical random coil CD 
spectrum with a strong minimum at 198 nm and a weak minimum at 225 nm commonly 
observed for disordered proteins (Figure 2.13B, solid line). A near identical CD spectrum 
was observed for rGRN-3 (Figure 2.13B, short dash) as previously reported.166 This is an 
interesting observation considering the high cysteine content (20%) within the protein. 
mGRN-3 displayed a spectrum which is typical of a poly proline type II (PPII) helix with 
a minimum at 201 nm and a less intense maximum at ~230 nm (Figure 2.13B, dash).171, 
172 It is increasingly common to observe PPII conformational for IDPs173-176, due to 
similar arrangement of amide dipoles within their geometries.177 The observations are 
more evident from the residual spectra of GRN-3 (Figure 2.13C, solid line) and mGRN-3 
(Figure 2.13C, dashed line) obtained after subtracting the rGRN-3 spectrum. The dotted  
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Figure 2.13 Structural Characterization of GRN-3, and mGRN-3. 
Α, 1H-15N SoFast HMQC NMR spectra of GRN-3, and mGRN-3. B, Far-UV circular dichroism (CD) spectra of native GRN-3 (solid 
line), mGRN-3 (dashed line), and rGRN-3 (short dashed line). Both GRN-3 and rGRN-3 show minima at 198 nm typical of random 
coil whereas mGRN-3 shows a minimum at 202nm and a maximum at ~230 nm corresponding to a PP2 helix. C, Residual spectra for 
GRN-3 (solid) and mGRN-3 (dash) after subtracting the CD spectrum of rGRN-3. The line at 0 (short dash) is the baseline obtained 
by zero correcting rGRN-3 spectrum. 
line at 0 in Figure 2.13C is the baseline obtained by zero-correcting rGRN-3 spectrum. 
The potentially conflicting observations from NMR and CD data for GRN-3 can be 
explained from the fact that disulfide bonds, which if present in a ladder-like arrangement 
as observed in GRN4100, hold the loops such that the protein backbone show minimal 
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conformational freedom. This may show distinct magnetic environment responsible for a 
good spectral dispersion in NMR yet, the backbone amide dipoles are not in a typical β-
sheet environment to display * transition at 216 nm in CD. These findings seem to 
indicate that although disulfide bonds are important to induce structural order in GRN-3, 
they do not induce the formation of canonical secondary structures but rather disordered 
loops that are dynamic. 
2.6.4 mGRN-3 has More Solvent-Exposed Hydrophobic Surfaces as Compared to 
GRN-3 
To evaluate the structural differences in GRN-3 and mGRN-3, the solvent-
exposed hydrophobic surfaces were qualitatively estimated the using 8-anilino-1-
naphthalene sulfonic acid (ANS). ANS is an extrinsic dye which exhibits weak 
fluorescence in polar environments but shows strong fluorescence with a distinct blue 
shift in its emission wavelength upon binding to the solvent-exposed hydrophobic 
residues of proteins.178 ANS has been widely used to study protein folding/unfolding and 
structure of the molten globule states.179 Upon incubating 25 μM GRN-3 or mGRN-3 
with 500 μM ANS, the fluorescent intensity with mGRN-3 was significantly higher than 
that with GRN-3 (Figure 2.14A). This indicates that mGRN-3 has more solvent-exposed 
hydrophobic surfaces than GRN-3. This evaluation is in agreement with the 1H-15N 
HMQC NMR data which shows mGRN-3 to be more disordered and collapsed as 
compared to GRN-3 (Figure 2.13A). In addition, the solvent accessibility of the single 
tryptophan residue (W28) in GRN-3 was examined using Stern-Volmer analysis where 
the fluorescence of the W residue was monitored with the increasing concentration of a 
quencher (acrylamide). A significant deviation from linearity was observed in case of 
 51 
GRN-3 (Figure 2.14B, ) indicating that tryptophan undergoes dynamic quenching 
indicative of the probe being solvent exposed155, whereas, the deviation observed in case 
of mGRN-3 was relatively insignificant (Figure 2.14B, ). Thus, the solvent 
accessibility of W28 is more in GRN-3 than it is in mGRN-3, perhaps, due to more 
collapsed structure of mGRN-3 the W residue may be buried inside the hydrophobic core. 
 
Figure 2.14 Structural differences between GRN-3 and mGRN-3. 
Α, Differential interaction of 8-anilino-1-naphthalene sulfonic acid (ANS) to GRN-3 and mGRN-3 at 25 μM, indicating differences in 
the exposed hydrophobic surfaces in GRN-3 and mGRN-3. Β, Stern-Volmer plot of GRN-3 () and mGRN-3 () using acrylamide 
as the quenching agent. 
2.6.5 Disulfide Bonds Contribute to the Overall Stability of GRN-3. 
To obtain specific insights into the role of disulfide bonds in the structure and 
stability of GRN-3, the protein was subjected to detergent-induced thermal denaturation. 
It is known that high concentrations of SDS (> 1%) induce rod-like or necklace like 
structures to polypeptides that a largely exhibit an -helical structure180-182.  It has also 
been shown that SDS-induced thermal denaturation of proteins that lack significant 
secondary structure to -helical structures, is a convenient way to monitor stability by 
CD183. Therefore, GRN-3, mGRN-3 or rGRN-3 samples were denatured with 1% SDS 
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(35 mM) and the conversion from the random coil to helical structure was monitored as a 
function of temperature by CD spectroscopy. As expected, largely disordered rGRN-3 
instantly melted into an α-helix in presence of SDS prior to the heat treatment at 10 °C 
(Figure 2.15A, rGRN-3, dotted line) and remained largely α-helical over the temperature 
range up to 90 °C (Figure 2.15A and Figure 2.15B, Δ). GRN-3, on the other hand, 
showed no appreciable changes in the random coil structure at 10 °C, and it remained in 
largely disordered form up to 90 °C (Figure 2.15A, GRN-3, dotted line and Figure 2.15B, 
■), with only a small deviation from the characteristic random coil to a spectrum towards 
α-helical structure with a minimum at 207 nm and a decrease at 220 nm (Figure 2.15A, 
GRN-3, dashed line, and Figure 2.15B, ■). A similar response was observed for mGRN-3 
with the protein remaining as largely disordered throughout the temperature range 
(Figure 2.15A and Figure 2.15B, ○). It is clear that both GRN-3 and mGRN-3 resist 
denaturation by SDS and remain disordered even with the increase in the temperature 
exhibiting robust thermal stability, a rather unusual characteristic of IDPs. Perhaps, this 
can be attributed to the presence of six intramolecular disulfide bonds in GRN-3, which 
resist the formation of ‘necklace’ or ‘rod-like’ helical structures known when SDS 
interacts with polypeptides180-182, 184. If disulfide bonds are the main reason for the 
structural stability, abrogation of these should make the protein amenable to denaturation, 
which is precisely what is observed with rGRN-3. Secondly, in light of high stability of 
GRN-3 and mGRN-3 for SDS denaturation, we wanted to see whether this stability 
reflects in electrophoretic mobility. As observed earlier (Figure 2.10C, fraction 48), under 
both reducing and non-reducing conditions with heat treatment (boiling the sample with 
1% SDS for five minutes), GRN-3 electrophoreses as a single band at 6.3 kDa  
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Figure 2.15 Structural Stability of GRN-3, mGRN-3, and rGRN-3. 
Α, Far-UV CD spectra of GRN-3, mGRN-3, and rGRN-3 without SDS (solid line) and in presence of 1 % SDS at 10 °C (dotted line), 
and 90 °C (dashed line). Β, Difference in 198 nm (random coil) and 208 nm (α-helix) for GRN-3 (■), mGRN-3 (○), and rGRN-3 (Δ) 
plotted against increasing temperature in presence of 1% SDS. C, SDS-PAGE of GRN-3, mGRN-3, & rGRN-3 under reduced and 
non-reduced with heat treatment (lanes 1, 2, 5, 6, 9, & 10, respectively) and reduced and non-reduced without the heat treatment (lanes 
3, 4, 7, 8, 11, & 12, respectively). 
corresponding to the molecular weight of monomeric GRN-3 (Figure 2.15D, lanes 1 and 
2). However, both under reducing and non-reducing conditions but without the heat 
treatment, a band is observed between 40 and 50 kDa GRN-3 (Figure 2.15D, lanes 3 and 
4). Furthermore, in the presence of the reducing agent (βME), additional monomeric band 
was observed, which was absent in the βME untreated sample, reinforcing the inference 
that disulfide bonds are solely responsible for the stability and abnormal electrophoretic 
mobility of GRN-3. This unusual electrophoretic mobility was not observed in case of 
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mGRN-3 or rGRN-3 (Figure 2.15D, lanes 5 to 12) even though both mGRN-3 and 
rGRN-3 are more disordered than GRN-3 for reasons that remain uncertain. Many IDPs 
are notorious for their display of unusual mobility during electrophoresis, which is 
largely attributed to the reduced SDS binding and shape of the SDS-protein complex9 
2.7 Discussion and Conclusions 
The primary objective of this study was to identify the role of six disulfide bonds 
in the structure and dynamics of GRN-3 by investigating the structure of native GRN-3. 
In this context, the results presented here indicate that disulfide bonds play an intriguing 
role in inducing structural stability to the protein and raise some interesting aspects about 
the role of disulfide bonds in structural plasticity among IDPs. First, both E. coli and 
HEK cells are ineffective in making correct disulfide linkages indicated by the incapacity 
of both the cell types to generate intramolecularly disulfide bonded monomers 
exclusively. In E. coli, only 5% of the total protein expressed is monomeric while the 
remaining 95% forms different multimers with scrambled inter-molecular disulfide 
bonds, despite, the presence of thioredoxin tag and the oxidative environment of the 
engineered E. coli cells used for the expression. Surprisingly, even the mammalian 
(HEK) cells show some level of scrambled multimers and seem to be fully effective in 
generating monomers exclusively, in spite of having the adequate post-translational 
machinery required to form correct disulfide bonds. One plausible reason for this could 
be the high cysteine content of GRN-3 (20%) and the location of cysteines (four pairs of 
adjacent cysteines in the center with two single cysteines at each terminus; Figure 1.3) 
within its sequence. This unique arrangement could decrease the fidelity of protein 
disulfide isomerases (PDIs) to catalyze formation of correct disulfide bonds. Moreover, 
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in cells GRNs are produced by the proteolytic cleavage of their precursor, PGRN which 
could further exacerbate the complications in disulfide bonds formation as PGRN has 90 
cysteines forming 45 disulfide bonds (7.5 tandem repeats of GRNs; Figure 1.3). Indeed, 
disulfide bonded multimeric isoforms of PGRN have been reported previously in HEK 
cells.185 
The second interesting inference that can be drawn from this study is that the 
disulfide bonds solely dictate the structure of GRN-3 and depending upon whether the 
bonds are scrambled or absent altogether the protein is either partly disordered or 
completely disordered. The 2D-NMR HMQC data along with the other biophysical 
evidence presented in section 2.2.3 confirms rGRN-3 to be intrinsically disordered. 
Interestingly, the HMQC data also suggests that mGRN-3, with scrambled disulfide 
bonds, is largely disordered but shows more degree of order as compared to rGRN-3. In 
contrast, monomeric GRN-3 shows significant spectral dispersion suggestive of a well-
defined structure for the protein. These findings confirm our hypothesis that the structure 
of GRN-3 is mainly dictated by the six intra-molecular bonds and the scrambling or the 
abrogation of the disulfide bonds result in a protein with partial or complete loss of 
structure. However, the CD data suggests that GRN-3 is unstructured as indicated by the 
random coil spectrum commonly observed for disordered proteins. rGRN-3 also shows 
an identical CD spectrum. This discrepancy in the NMR and the CD data could, perhaps, 
arise from the arrangement of the disulfide bonds in GRN-3 structure and the way they 
stabilize the disordered structure. The possibility of the conserved cysteines in GRN-3 
forming a ladder-like disulfide bond arrangement as observed for GRN4 (Figure 2.16A, 
dark grey)100 is high even though GRN-3 shows only 55% sequence identity with GRN-4. 
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In fact, the GRN-3 structure predicted using the I-TASSER structure prediction tool186, 187 
(Figure 2.16Β, light grey), aligns with the GRN4 structure with root mean square 
deviation (rmsd) score of 1.02 over 56 residues (Figure 2.16C) suggestive of similar 
structure at least at the N-terminus.  
 
Figure 2.16 Structure alignment of Grn4 and GRN-3. 
Α, Solution NMR structure of Grn4 (pdb – 2jye) with disulfide bonds shown as black sticks. Β, GRN-3 structure predicted based on 
the primary amino acid sequence using the I-TASSER prediction tool with predicted disulfide linkages shown in black C, Alignment 
of Grn4 and GRN-3 structures performed using PyMol; dark grey is Grn4 and light grey is GRN-3. Disulfides bonds are shown as 
black sticks. 
From this alignment, it can be assumed that the structural order in GRN-3 is mainly 
achieved by the disulfide bonds that from the fulcrum to the structure stabilizing the 
loops surrounding them. Such a structure has minimal secondary structure content (only 
short segments of β-strands are observed in GRN-4 or GRN-3) and the conformational 
freedom of the loops seems to be curtailed by the central shaft made of disulfide bonds. 
The other family of proteins bearing closest resemblance to a disordered structure 
stabilized by disulfide bonds include the epidermal growth factor domain containing 
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proteins like the epidermal growth factor (EGF), and transforming growth factor α (TGF-
α)92, 188, and the kringle domain-containing family of proteins such as the hepatocyte 
growth factor96, proteases involved in blood clotting like prothrombin, and 
plasminogen97, apolipoprotein98, and tissue plasminogen activator.99 Both the EGF 
domain and kringle domains are characterized by disordered loops with minimal well-
defined secondary structure stabilized by three disulfide bonds. 
 
Figure 2.17 Structural fold similarity between GRN-3, EGF, and ApoA kringle domain. 
Α, Similarity between far-UV CD spectrum of GRN-3 (solid line) and human EGF (dashed line). Inset, Structural fold similarity 
between the predicted structure of GRN-3 and solution NMR structure of EGF (pdb – 2kv4). Β, Structural fold similarity between 
predicted GRN-3 structure and ApoA kringle domain (pdb - 4bvd). 
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The murine EGF exhibits a striking resemblance to the unique stacked β-sheet domain 
observed for the N-terminal domain of GRN4 (Figure 1.5A). The comparison of the far-
UV CD spectra of GRN-3 and that of human EGF showed striking resemblance, with the 
latter showing the PP2-helix profile (Figure 2.17A). The HSQC spectrum of human EGF 
shows well-dispersed resonances189 whereas the CD spectrum indicates PP2-helix similar 
to what observed for GRN-3.  Further, the predicted structure of GRN-3 and the solution 
NMR structure of human EGF (pdb – 2kv4)189 show similar structural fold (Figure 
2.17A, inset). Additionally, the kringle domain of ApoA also has similar structural fold 
(Figure 2.17B). 
Though this study establishes the vital role of disulfide bonds in the structure of 
GRN-3, it raises questions on their necessity and their inability to induce secondary 
structure in the protein. From the thermal stability data, it is clear that disulfide bonds, 
alone, impart a remarkable thermal stability to GRN-3. Perhaps, it can be speculated that 
the fulcrum of disulfide bonds holds the loops in place imparting stability to an otherwise 
flexible protein but maintain some degree of structural plasticity. Further, this partial 
plasticity could potentially be responsible for the multifunctional roles of IDPs. Such 
pluripotent structures of IDPs leading to multifunctional roles are now well established.9, 
152, 165 This study brings forth some interesting aspects of the role of disulfide bonds in 
GRN-3 structure; the most striking of which is the delicate handshake between disulfides 
and disorder towards maintaining stability and plasticity. 
 
 59 
CHAPTER III - INTERACTIONS BETWEEN GRN-3 AND A AND THEIR 
IMPLICATIONS IN AD PATHOLOGY 
3.1 Hypothesis and Rationale 
As detailed in section 1.4.1, several evidences point towards the involvement of 
GRNs in AD. We hypothesize that GRN-3 directly interacts with Aβ during acute 
inflammation and modulates the latter’s aggregation and neuronal toxicity. This 
chapter is focused on the interaction between GRN-3 and Aβ by biophysical methods and 
are detailed and discussed in the following sections. 
3.2 Results 
3.2.1 GRN-3 Directly Interacts with Aβ42 Monomers with a Moderate Binding 
Affinity. 
To investigate the interactions between GRN-3 and Aβ42, tetra-methyl rhodamine 
(TMR) labeled Aβ was used as a fluorescence probe and increasing concentrations of 
GRN-3 were titrated on it. The concentration of TMR-A was kept constant at 4 μM 
throughout the titrations. The samples were excited at 550 nm (excitation λmax for 
rhodamine) and the changes in the fluorescence emission of rhodamine labeled Aβ42 
upon titration of GRN-3 were monitored at 580 nm. The normalized fluorescence 
intensities expressed as fraction bound were plotted against the stoichiometry yielding an 
exponential binding isotherm (Figure 3.1, ). The binding isotherm was fitted using the 
following two-site binding model (see equation below) to obtain two binding affinities, 
80 nM, and 2500 nM. 
𝑦 =
𝐵𝑚𝑎𝑥1 ∗ 𝑥
𝐾1 + 𝑥
+ 
𝐵𝑚𝑎𝑥2 ∗ 𝑥
𝐾2 + 𝑥
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Figure 3.1 Binding interactions between GRN-3, mGRN-3, & BSA and TMR-Aβ42 
monomer. 
The binding isotherm is fitted with a two-site binding model. 
where y is the fraction bound, x is the stoichiometry, 𝐵𝑚𝑎𝑥1 and 𝐵𝑚𝑎𝑥2 are the arbitrary 
parameters that are floated, and 𝐾1 and 𝐾2 are the binding constants for the two sites. 
Thus, from the two binding constants obtained, the binding affinity between GRN-3 and 
Aβ42 monomer is an order of magnitude stronger for one site as compared to the other. 
The binding interactions between mGRN-3 and TMR-Aβ42 were probed in a similar as 
described above. The response obtained from the titration of mGRN-3 indicated that the 
interaction between mGRN-3 and TMR-Aβ42 was significantly weaker as compared to 
that of GRN-3 (Figure 3.1, ). BSA, the negative control used for the assay, didn’t show 
any interaction with TMR-Aβ42 as expected (Figure 3.1, ■). 
3.2.2 GRN-3 Accelerates Aβ42 Aggregation in a Concentration-Dependent Manner 
The effects of GRN-3 and mGRN-3 on Aβ42 aggregation were monitored using 
thioflavin-T (ThT) fluorescence, immunoblotting, and far-UV CD. ThT is an extrinsic 
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fluorescent dye that shows an increase in its fluorescence intensities upon binding to the 
β-sheet rich Aβ aggregates. It is routinely used to monitor Aβ aggregation.190 Freshly 
purified, aggregate-free Aβ42 monomers (20 μM) were incubated with sub-
stoichiometric (4 μM), stoichiometric (20 μM), and super-stoichiometric (40 μM) 
concentrations of GRN-3 and mGRN-3 in 20 mM Tris, pH 6.5 and 50 mM NaCl at 37 °C 
under quiescent conditions. ThT fluorescence was measured at 12, 18, 24, 48, 72, and 96 
h time points. Aβ42 co-incubated with super-stoichiometric concentration of GRN-3 
showed accelerated aggregation within first 12 h of co-incubation as indicated by 
increase in the fluorescence intensity and the absence of the lag phase (Figure 3.2A, ) 
as compared to the Aβ42 control incubated and monitored under identical conditions 
(Figure 3.2A, □). Aβ co-incubated with stoichiometric concentrations (Figure 3.2A, ▲) 
of GRN-3 showed a slight increase in the fluorescence intensity, however, the lag time 
was similar to that of control Aβ. At sub-stoichiometric (Figure 3.2A, ) concentration, 
the aggregation profile of co-incubated Aβ was identical to that of control for the first 24 
h. Aliquots of the co-incubated samples were electrophoresed at 12 and 24 h and 
immunoblotted using an Aβ specific antibody, Ab5, to assess if the increase in the ThT 
fluorescence for Aβ co-incubated with 40 μM GRN-3 was due to formation of high 
molecular weight aggregates. An intense band corresponding to a high molecular weight 
aggregate (> 260 kDa) was observed for Aβ co-incubated with 40 μM GRN-3 with 
concomitant decrease in the monomeric band between 3.5 and 10 kDa (Figure 3.2C, lane 
4) after 12 h of co-incubation whereas no such band was observed for Aβ control and Aβ 
co-incubated with 4 and 20 μM GRN-3 (Figure 3.2C, lanes 1, 2, & 3, respectively). This 
indicates that the increase in the ThT fluorescence observed at 12 h for Aβ co-incubated 
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with 40 μM GRN-3 was indeed due to formation of Aβ aggregates. After 24 h, a high 
molecular weight band was observed for Aβ co-incubated with all three concentrations of 
GRN-3, however, the intensity of the band was highest for 40 μM GRN-3, followed by 
20 μM, and least for 4 μM GRN-3. A faint aggregate band was also observed for Aβ 
control. 
 
Figure 3.2 Effect of GRN-3 on Aβ42 aggregation. 
Over time ThT fluorescence measurements of 20 μM Aβ42 alone (□) and Aβ42 co-incubated with 4 μM (●), 20 μM (▲), and 40 μM 
() GRN-3 (A) and 4 μM (●), 20 μM (▲), and 40 μM () mGRN-3 (B) in 20 mM Tris, pH 6.5 and 50mM NaCl at 37 °C under 
quiescent conditions. C, Immunoblots of 20 μM Aβ42 alone and Aβ42 co-incubated with 4 μM, 20 μM, and 40 μM GRN-3 and 
mGRN-3 at 12 h and 24 h time-points. 
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In contrast, Aβ co-incubated with same concentrations of mGRN-3, as GRN-3, 
did not show any increase in the ThT fluorescence (Figure 3.2B) and no aggregate band 
was observed for the co-incubated samples on the immunoblot at 12 h and 24 h time 
point (Figure 3.2C, lanes 5, 6, & 7).  Since GRN-3 promoted aggregate formation within 
12 h of coincubation, the possibility of GRN-3 augmenting Aβ42 aggregate formation 
before 12 h was investigated by co-incubating freshly purified 20 μM Aβ42 monomers 
with 40 μM GRN-3 and aliquots were electrophoresed after 1, 3, & 6 h of co-incubation. 
Interestingly, GRN-3 was able to promote formation of aggregates within 1 h of 
coincubation (Figure 3.3, lane 2) and the amount of the aggregate formed increased after 
3 and 6 h of co-incubation as evident from the intensity of the band (Figure 3.3, lane 3 & 
4, respectively). The Aβ42 monomer didn’t aggregate within the experimental time frame 
(Figure 3.3, lane 1). 
 
Figure 3.3 Time-dependent Aβ42 aggregation co-incubated with GRN-3. 
Lane 1, 20 μM Aβ42 monomer alone after 6 h; Lane 2, 20 μM Aβ42 + 40 μM GRN-3 after 1 h; Lane 3, 20 μM Aβ42 + 40 μM GRN-3 
after 3 h; Lane 4, 20 μM Aβ42 + 40 μM GRN-3 after 6 h. 
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Furthermore, the co-incubated samples were monitored via far-UV CD to 
investigate if the augmentation in aggregation is complemented by changes in the 
secondary structure of Aβ42 monomers from random coil to β-sheet. The control Aβ42 
sample showed the random coil spectrum immediately after incubation i.e. at 0 h (Figure 
3.4A, dashed line) and it remained random coiled even after 12 h (Figure 3.4A, dotted 
line) and 24 h (Figure 3.4A, solid line) of incubation at 37 °C. For Aβ42 co-incubated 
with 40 μM GRN-3, the spectrum was random coil at 0 h (Figure 3.4B, dashed line), 
however, after 12 h of incubation a slight negative minimum was observed at 216 nm 
indicating formation of β-sheet (Figure 3.4B, dotted line). The change can be better 
appreciated by the difference spectra (observed – control) shown in Figure 3.4B, inset, 
dotted line). This change in the secondary structure of Aβ co-incubated with 40 μM 
GRN-3 corroborates with the increased ThT fluorescence and aggregate band observed 
for this sample as detailed previously. The change was pronounced after 24 h of co-
incubation with a distinct negative minimum at 216 nm and a positive maximum at 198 
nm, typical of β-sheet structure observed for high molecular weight aggregates of Aβ 
(Figure 3.4B, solid line). The change is pronounced in the difference spectra (Figure 
3.4B, inset, solid line). For Aβ co-incubated with 4 μM GRN-3, the change in the 
secondary structure was observed only after 24 h as seen in the difference spectrum 
(Figure 3.4C, inset, solid line) which also correlates with the high molecular weight band 
observed in the immunoblot (Figure 3.4C, 24 h, lane 3). Surprisingly, Aβ co-incubated 
with 4 and 40 μM mGRN-3 also showed a change in the secondary structure after 24 h 
but no high molecular weight aggregate band was observed in 24 immunoblot for both  
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Figure 3.4 Changes in the secondary structure of Aβ42 co-incubated with GRN-3. 
Α, Far-UV CD spectrum of 20 μM Aβ42 incubated in 20 mM Tris, pH 6.5 and 50 mM NaCl at 0 (dashed line), 12 (dotted line), & 24 
h (solid line) time-points. Far-UV CD spectrum of 20 μM Aβ42 at 0 (dashed line), 12 (dotted line), & 24 h (solid line) time-points, co-
incubated with 40 μM GRN-3 B, 4 μM GRN-3 C, 40 μM mGRN-3 D, and 4 μM mGRN-3 E, The samples were incubated in 20 mM 
Tris, pH 6.5 and 50 mM NaCl at 37 °C under quiescent conditions. Β, & C, inset, Difference spectra (observed – control) 
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the concentrations (Figure 3.4C, 24 h, lanes 5, 6, & 7). However, the spectra didn’t show 
the typical β-sheet minimum at 216 nm but resembled an intermediate structure having 
both random coil and β-sheet type structures indicative of some intermediate formed 
along the aggregation pathway. These results indicate that GRN-3 augments aggregation 
of Aβ42 in a concentration-dependent manner in which super-stoichiometric 
concentrations abolish the lag time observed during canonical Aβ aggregation to promote 
the formation of high molecular weight aggregates. 
3.2.3 GRN-3 Promotes High Molecular Weight Aggregates of Oligomers. 
Aβ can aggregate to form fibrils via multiple different pathways generating non-
canonical neurotoxic oligomers.191-196 Large Fatty Acid Derived Oligomers (LFAOs), 
generated in our lab in presence of fatty acid interfaces are established as those formed 
along ‘off-pathway’.23 LFAOs are kinetically trapped along an alternate pathway that are 
incapable of converting into fibrils for an extended period of time. LFAOs also undergo 
self-propagative replication by quantitatively converting more monomers into similar 
toxic oligomers.24 
Since GRN-3 was able to interact with Αβ monomers and promote aggregates, we 
questioned whether GRN-3 will be able to interact with specifically with oligomers. To 
do so, we used LFAOs as model oligomers to investigate. Specifically, we wanted to 
explore the effect of GRN-3 on the self-propagative replication of LFAOs. Freshly 
purified LFAOs (1 μM) were incubated with freshly purified seed-free Aβ42 monomers 
(20 μM) in presence of 40 μM GRN-3 in 20 mM Tris, pH 8.0 at room temperature for 72 
h. Control reactions, without the GRN-3, were also incubated under similar conditions. 
The samples were electrophoresed and immunoblotted after 72 h. No change was 
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Figure 3.5 Effect of GRN-3 on LFAO replication. 
Lane 1, 20 μM Aβ42 monomer alone; Lane 2,1 μM LFAO alone; Lane 3, 20 μM Aβ42 monomer + 1 μM LFAO; Lane 4, 1 μM LFAO 
+ 40 μM GRN-3; and Lane 5, 20 μM Aβ42 monomer + 1 μM LFAO + 40 μM GRN-3. 
observed in Aβ42 monomer alone and LFAO alone controls after 72 h of incubations 
(Figure 3.5, lanes 1 and 2, respectively). As expected, there was an increase in the 
amount of LFAOs incubated with Aβ42 monomers as indicated by the intense band 
observed in Figure 3.5, lane 3. This increase is due to the unique self-propagative 
replication of LFAOs as previously reported.24 However, LFAOs co-incubated with 40 
μM GRN-3 alone and with 40 μM GRN-3 and Aβ42 monomers in separate reactions, 
formed fibrils instead of undergoing their characteristic self-propagation (Figure 3.5, 
lanes 5 and 6, respectively). This suggests that GRN-3 is able to interact with Aβ 
irrespective of whether monomeric or oligomeric. 
3.3 Discussion and Conclusions 
Discerning the causes of AD pathogenesis has been a continuous pursuit to 
understand the etiology of the disease. In this context, determining the role played by 
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neuroinflammatory pathways and the myriads of players involved in these pathways in 
the onset and the progression of AD is vital. One of several such critical players are 
PGRN and GRNs. Though several clinical evidences support the direct role of PGRN & 
GRNs in AD pathology, the mechanistic details remain elusive. In this chapter, we 
provide a proof of concept for involvement of GRN-3 in AD pathology by showing direct 
interactions between GRN-3 and Aβ, which supports our hypothesis on inflammation-
induced neurodegeneration. The data presented here indicate that GRN-3 interacts with 
Aβ42 monomers at sub-micromolar concentrations. Moreover, the data suggests that the 
interactions may potentially involve two binding sites with an order of magnitude 
differences in the binding affinities. Further, we show that GRN-3 rapidly augments Aβ 
aggregation in a concentration- and time-dependent manner to form high molecular 
weight fibril-like aggregates. In chapter IIB we established that GRN-3 has a well-
defined structure, potentially a β-sheet type structure, whereas mGRN-3 has a collapsed 
disordered structure due to the disulfide bond scrambling. There is a possibility that 
GRN-3 may act as a potential template for Aβ aggregation. However, more detailed 
analyses of this phenomenon are warranted before this claim can be substantiated and 
will be the future direction of this study. Nevertheless, we have shown that, at super-
stoichiometric concentrations, GRN-3 can induce a rapid change in the secondary 
structure of Aβ monomers from random coil to β-sheet. We have also shown that GRN-3 
promotes fibrils formation not only from Aβ monomers but also from specific Aβ 
oligomers called LFAOs. Taken together, these results provide a proof of concept to 
support our hypothesis. Further experimentation necessary to determine the precise 
molecular details underlying GRN-3-Aβ interactions are ongoing in the lab. 
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CHAPTER IV – OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
4.1 Overall Conclusions 
The primary aim of this study was to understand the structure of GRN-3 - one of 
the seven GRNs proteolytically cleaved from their precursor PGRN with an objective of 
correlating the information gained to its functions. As mentioned earlier, GRN-3, like 
other six GRNs, contains twelve conserved cysteines and forms six disulfide bonds. 
Thus, it was important to discern the role of the disulfide bonds in the structure of GRN-3 
which potentially could dictate its functions, especially, its function in AD. The following 
overall conclusions can be drawn from this study: 
➢ Abrogation of the disulfide bonds renders GRN-3 (rGRN-3) completely 
disordered which exists as an IDP at low concentrations. 
➢ rGRN-3 shows interesting conformational dynamics; it dimerizes at elevated 
concentrations and forms a fuzzy complex. 
➢ rGRN-3 exhibits a pro-inflammatory function in CNS, indicated by the 
activation of NF-B in neuroblastoma cells. 
➢ Cellular machinery, especially in E. coli seems to be rather inefficient in 
generating native GRN-3 with correct disulfide bonds. In E. coli, only 5% of 
the total expressed GRN-3 is monomeric with all 12 cysteines forming 
intramolecular disulfide bonds. GRN-3 expressed in human embryonic kidney 
(HEK) cells too, do not generate intramolecularly disulfide-bonded monomers 
exclusively although better than E. coli. Both E. coli and HEK cells form 
heterogeneous isoforms of multimeric GRN-3 (mGRN-3) consisting of 
scrambled disulfide bonds to varying degrees. 
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➢ GRN-3 shows a well-defined ordered structure as compared to that of mGRN-
3 or rGRN-3. mGRN-3 has a largely disordered structure but is more ordered 
as compared to that of rGRN-3. 
➢ The ordered structure of GRN-3 and the lack of thereof in rGRN-3 or mGRN-
3 confirms that disulfide bonds solely dictate the structure of GRN-3 and impart 
stability to a disordered protein. They mediate an unusual cooperation between 
structural stability and plasticity which potentially can affect the functions of 
the protein. 
➢ GRN-3 augments Aβ aggregation by interacting with Aβ monomers and 
LFAOs providing a proof of concept for the role of GRN-3 in AD pathology.  
4.2 Future Directions 
Future studies will be directed towards solving the structure of monomeric GRN-
3. The HMQC data indicated that GRN-3 has a well-defined structure and elucidating the 
structure will be very critical. In short, triple resonance spectroscopy will be used where 
GRN-3 will be doubly labeled with 13C and 15N and the cross-peak correlations will be 
assigned to obtain the structure. 
The role of GRN-3, mGRN-3, and rGRN-3 in AD pathogenesis will be explored 
in further details. 2D-NMR spectroscopy will be used to confirm the binding interactions 
between GRN-3 and Aβ42. Briefly, Aβ will be co-incubated with 15N labeled GRN-3 and 
the changes in the 2D-NMR spectrum of GRN-3 will be monitored. The 2D-NMR 
spectrum of GRN-3 without Aβ42 will be used as a control. The morphology and 
structure of high molecular weight aggregates of Aβ promoted by GRN-3 will be 
investigated using atomic force microscopy. 
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CHAPTER V – MATERIALS AND EXPERIMENTAL PROCEDURES 
5.1 Materials 
Wild-type Αβ42 peptide was obtained commercially from the Peptide Synthesis 
facility at the Mayo Clinic (Rochester, MN). Monoclonal antibody, Ab5 specific for Αβ1-
16 was obtained from Mayo Clinic (Jacksonville, FL). The secondary HRP conjugated 
anti-mouse anti-Fc antibody was obtained from Sigma (St. Loius, MO). All the gel 
electrophoresis and immunoblotting apparatus and buffers were procured from BioRad 
Laboratories, (Hercules, CA). The RP-18 LiChroCART HPLC column was obtained 
from Merck, Germany. The semi-preparative Jupiter® 5 μm C18 reverse phase HPLC 
column was purchased from Phenomenex, California. All the other chemicals and 
consumables were procured from VWR, Inc. or Fisher Scientific unless otherwise 
indicated. 
5.2 Experimental Procedures 
5.2.1 Cloning of Human GRN-3 in E. coli. 
Cloning and modifications of the plasmid were carried out at the molecular 
cloning facility at Florida State University. The GRN-3 cDNA containing a Y24W 
mutation to facilitate fluorescence detection as well as NcoI and XhoI restriction enzyme 
sites at N- and C-termini, respectively, was synthesized commercially (Genewiz Inc.). 
These restriction sites were used to insert GRN-3 cDNA into a pET32b expression vector 
(Novagen). The commercially available pET32b plasmid facilitates protein expression as 
a trxA-GRN-3 fusion containing both N- and C-terminal hexa-histidine tags. The 
enterokinase cleavage site separating thioredoxin from the protein leaves an unwanted 
His-tag at the C-terminus of the expressed protein. In order to circumvent this obstacle, 
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the plasmid was modified to remove the C-terminal His-tag by introducing a stop codon 
downstream from GRN-3 cDNA. In addition, the enterokinase cleavage site along with 
the spacer DNA were deleted so that the GRN-3 cDNA was present upstream from a 
preexisting thrombin cleavage site. This modification enabled the expression of GRN-3 
protein with a trxA fusion partner and only the N-terminal His-tag. The modified 
plasmids containing the GRN-3 construct were expressed in the E. coli Origami 2(DE3) 
strain (Novagen) for purification of rGRN-3 and in the E. coli SHuffleTM strain (NEB) for 
purification of GRN-3. The transformed cells expressing the recombinant trxA-GRN-3 
fusion protein were grown at 37 °C (Origami) or 30 °C (SHuffle) in 2 L baffled culture 
shake flasks containing 1 L LB medium supplemented with 100 μg mL-1 of ampicillin. 
Expression of the protein was induced by adding isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to a final concentration of 0.9 mM for Origami strain and 0.1 mM for SHuflle 
strain when the optical density of the culture media was between 0.5 and 0.7 AU, as 
measured by UV-absorbance at 600 nm. Following 4 hours of induction at 37 °C 
(Origami) or 6 hours of induction at 30 °C (SHuffle), cells were harvested by 
centrifuging (14000xg, 4 °C) and used immediately or stored at -20 C. 
5.2.2 Purification of Recombinant rGRN-3. 
Cell pellets from 2 L of culture were thawed at room temperature and 
resuspended in 30-40 mL of equilibration buffer (50 mM Tris, pH 6.5, 300 mM NaCl, 10 
mM imidazole, 2 M urea) containing 0.5 mM phenylmethylsulfonyl fluoride (PMSF). 
The cell suspension was sonicated for 2 minutes (20-second burst with 1-minute rest) on 
ice and centrifuged at 9200xg to remove debris. The supernatant was loaded onto Ni2+-
NTA beads in a flex column pre-equilibrated with five-bed volumes of the equilibration 
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buffer. The column was then rocked for 1 hour at room temperature, and the supernatant 
was allowed to flow through the beads under gravity and collected as a flow-through 
fraction. The beads were then sequentially washed with 100 and 120 mL of buffer (50 
mM Tris, pH 6.5, 300 mM NaCl) containing 60 and 80 mM imidazole, respectively. The 
trxA-rGRN-3 fusion protein was eluted using 20 mL of 300 mM imidazole in 50 mM 
Tris, pH 6.5, and 300 mM NaCl. The eluate was then reduced with ~10 fold molar excess 
of the reducing agent, tris(2-carboxyethyl) phosphine (TCEP), by rocking for 1 hour at 
room temperature and then diluted 10 times with 50 mM Tris, pH 6.5, and 300 mM NaCl. 
The protein was then dialyzed to remove TCEP and imidazole at room temperature 
against a buffer of 0.2 mM Tris, pH 6.5, and 0.5 mM NaCl and using a 10 kDa MWCO 
dialysis membrane (Spectrum Labs). The dialysate was then lyophilized using vacuum 
evaporation and resuspended in sterile water such that the final buffer concentration was 
20 mM Tris, pH 6.5, and 50 mM NaCl. Concentration of the fusion protein was measured 
using UV-Vis spectroscopy with a molar extinction coefficient of 20355 M-1cm-1 at 280 
nm.150 On average, 7-9 mg of fusion protein was obtained per liter of induced cells. The 
fusion protein was aliquoted in 2 mg mL-1 fractions and used immediately or stored at – 
20 C. Further purification of rGRN-3 was accomplished by digesting 2 mg aliquots of 
the protein via addition of restriction grade thrombin (Novagen) (10 U) to cleave both 
trxA and the His-tag. The reaction was incubated in a 37 °C water bath for 22-24 hours 
with 5 U of enzyme added at the start of the incubation and the remaining 5 U added after 
8-10 hours of incubation. Completion of the cleavage reaction was confirmed by SDS-
PAGE analysis (data not shown). rGRN-3 protein was then fractionated using a 
LiChroCART C-18 reverse phase HPLC column (Merck Inc, Germany) with a gradient 
 74 
of 30-90% acetonitrile containing 0.1% TFA. Freshly purified rGRN-3 was used for 
every experiment, and the protein was used within 2 h of purification to avoid potential 
re-oxidation issues. 
5.2.3 Purification of GRN-3 
Cell pellets from 4 L of culture were thawed at room temperature and 
resuspended in 120 mL of equilibration buffer (50 mM Tris, pH 6.5, 300 mM NaCl, 10 
mM imidazole, 2 M urea) containing 0.5 mM phenylmethylsulfonyl fluoride (PMSF). 
The cell suspension was sonicated for 2 and a half minutes (40-second burst with 1-
minute rest) on ice and centrifuged at 9200xg to remove debris. The supernatant was 
incubated with Ni2+-NTA beads pre-equilibrated with five-bed volumes of the 
equilibration buffer and stirred gradually at 4 °C for 1 hour. The supernatant was then 
allowed to flow through the beads using a peristaltic pump and collected as a flow-
through fraction. The beads were then washed with 200 of buffer (50 mM Tris, pH 6.5, 
300 mM NaCl) containing 120 mM imidazole. The trxA-GRN-3 fusion protein was 
eluted using 50 mL of 400 mM imidazole in 50 mM Tris, pH 6.5, and 300 mM NaCl. The 
eluate was then dialyzed at 4 °C against a buffer of 2 mM Tris, pH 6.5, and 5 mM NaCl 
and using a 10 kDa MWCO dialysis membrane (Spectrum Labs). The dialysate was then 
concentrated 10 times using vacuum evaporation such that the final buffer concentration 
was 20 mM Tris, pH 6.5, and 50 mM NaCl. Concentration of the fusion protein was 
measured using UV-Vis spectroscopy with a molar extinction coefficient of 20355 M-
1cm-1 at 280 nm.150 On average, 8-10 mg of fusion protein was obtained per liter of 
induced cells. The fusion protein was then digested by addition of restriction grade 
thrombin (Novagen) 1U per 1 mg of the protein to cleave both trxA and the His-tag. The 
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reaction was incubated in a 37 °C water bath for 22-24 hours with half of the units of 
enzyme added at the start of the incubation and the remaining half were added after 8-10 
hours of incubation. Completion of the cleavage reaction was confirmed by SDS-PAGE 
analysis. GRN-3 protein was then fractionated using a semi-preparative Jupiter® 5 μm 
C18 reverse phase HPLC column (Phenomenex, CA) with height and internal diameter of 
250 mm and 10 mm, respectively with a gradient of 80 – 60 % acetonitrile containing 
0.1% TFA. Freshly purified GRN-3 was used for every experiment. The concentration of 
the protein was estimated spectrophotometrically using the calculated molar extinction 
coefficient of 6250 M-1cm-1 at 280 nm.150 
5.2.4 Expression and Purification of GRN-3 for 15N Labelling. 
For uniform labeling of the backbone and side chain amide nitrogens with 15N the 
cells were grown in M9 minimal medium with 15NH4Cl (Cambridge Isotope 
Laboratories, Inc., MA) as the sole nitrogen source. 10x M9 medium was prepared by 
adding 60g of Na2HPO4, 30g KH2PO4, 5 g of NaCl, and 5 g of 
15NH4Cl to 1 liter of H2O 
and sterilized by autoclaving at 121 °C, 15 psi for 20 mins. The 10% (v/v) of 10x M9 
medium was supplemented with 1% (v/v) of 100x trace elements solution, 2% (v/v) of 20 
% (w/v) Glucose, 0.1% (v/v) of 1M MgSO4, 0.1% (v/v) of 1M CaCl2, 0.1% (v/v) of 1 
mg mL-1 biotin, 0.1% (v/v) of 1 mg mL-1 thiamine and 100 μg mL-1 of ampicillin and the 
final volume was made up to 1000 ml. All the stock solutions, except for 20 % Glucose, 
were filter sterilized using 0.2 μm filter; glucose was sterilized by autoclaving at 121 °C, 
15 psi for 20 mins. The 100x trace elements solution was prepared by adding 5 g of 
EDTA, 0.83 g of FeCl3 x 6H2O, 84 mg of ZnCl2, 13 mg of CuCl2 x 2 H2O, 10 mg of 
CoCl2 x 6 H2O, 10 mg H3BO3, and 1.6 mg of MnCl2 x 6 H2O to 1 liter of sterilized H2O 
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and filter sterilized using a 0.2 μm filter. 15N-labeled GRN-3-trxA was expressed and 
purified using the same protocol as detailed in section 5.2.3. Further, 15N-labeled GRN-
3, mGRN-3, or rGRN-3 were purified using same protocols as detailed in sections 5.2.3 
& 5.2.2. The 15N-labeling was confirmed using MALDI-ToF by assessing the increase in 
the molecular weight. 
5.2.5 Cloning, Expression, and Purification of hGRN-3 from HEK Cells 
hGRN-3 was expressed and purified from human embryonic kidney cells by Dr. 
Kukar’s lab at the Emory university. The DNA sequences encoding Granulin-3 (AKA B) 
was codon optimized and custom synthesized by GenScript (Piscataway, NJ). The amino 
acid sequence for human GRN 3/B including the linker region at the carboxyl-terminal 
end was identified based on the Universal Protein Resource database (P28799l; 
GRN_HUMAN). The endogenous PGRN signal peptide (SP) sequence followed by a 
twin-Strep and FLAG tag was added to the amino-terminus of GRN-3. Synthetic GRN 
gene constructs were designed to add a 5’ HindIII (AAGCTT) site, a Kozak sequence 
(GCCACC) before the ATG start codon, a 3’ Stop codon, and a XhoI (TGACTCGAG) 
site. Following synthesis, each gene was inserted into the pcDNA3.1 (+) vector using a 
HindIII/XhoI cloning strategy.  All constructs were verified using DNA sequencing, 
restriction digests, and PCR amplification. Subsequently, primers were designed to 
remove the linker region of GRN-3; each construct was amplified via PCR, and 
subcloned into pcDNA3.1 (+) vector, and verified using DNA sequencing. Amino acid 
sequence for Granulin-3 without linker 4 (GRN-3) amino acid sequence: 
MWTLVSWVALTAGLVAGSAWSHPQFEKGGGSGGGSGGSAWSHPQFEKGASDY
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KDDDDKSVMCPDARSRCPDGSTCCELPSGKYGCCPMPNATCCSDHLHCCPQDT
VCDLIQSKCLS. 
HEK Expi293 cells were transfected with the pcDNA3.1 GRN-3 constructs and 
conditioned media was collected following the manufacturer’s protocol (Thermo-Fisher; 
Cat# A14635). GRNs were affinity-purified from conditioned media over Strep-Tactin 
XT Superflow resin using a slightly modified protocol as described by the manufacturer 
(IBA GmbH; Göttingen, Germany). The elutions containing recombinant GRNs were 
concentrated and desalted into PBS using Vivaspin 500 Protein Concentrators (molecular 
weight cut-off 50 kDa; GE Healthcare Life Sciences). The purity of recombinant GRNs 
was assessed by SDS-PAGE followed by colloidal coomassie dye G-250 protein stain 
(GelCode Blue; Thermo-Fisher) or silver stain (cat #24600; Thermo-Fisher) and 
estimated to be >95% pure. 
5.2.6 Ellman’s Assay 
The integrity of disulfide bond in GRN-3 or mGRN-3 or the lack thereof in 
rGRN-3 was tested using Ellman’s assay (Thermo Scientific). Ellman’s assay can be used 
to obtain the free cysteine content in a protein sample. The assay was performed using the 
manufacturer instructions (Thermo Scientific). 
5.2.7 Electrophoresis and Western Blotting 
SDS gel electrophoresis was carried out by using 8-16% or 4 – 20% Mini-Protean 
pre-cast gels (Biorad) and native gel electrophoresis was carried out by using in-house 
hand casted 14% polyacrylamide gels prepared in 1.5 M Tris, pH 8.8. For SDS gel 
electrophoresis, the samples were mixed with 4X or 2X reduced or non-reduced Laemmli 
buffer and were either treated with heat or not. For native gel electrophoresis, samples 
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were mixed with 2x native gel sample buffer (62.5 mM Tris, pH 8.8, 25% glycerol (v/v), 
1% bromophenol blue (w/v)) and electrophoresed using 1x native gel running buffer 
(2.5mM Tris, pH 8.8 and 19.2 mM glycine). Both SDS and native gels were stained using 
the Pierce silver staining kits (Thermo Scientific). For immunoblotting, the proteins were 
transferred on a 0.45 μm BioTraceTM NT nitrocellulose membrane (PALL Life 
Sciences/BioRad) and blocked with 5% non- fat dry milk in 1x phosphate buffered saline 
(PBS) with 0.1% tween 20. The blots were probed overnight with an Aβ42 specific 
antibody, Ab5 (Mayo Clinic, Florida). Blots were then incubated with a HRP-conjugated 
anti-mouse anti-Fc secondary antibody (Sigma) for 1-2 h and developed with ECL 
substrate for 2 min (Thermo Scientific). Images were obtained using a GelDoc molecular 
imager (Biorad). 
5.2.8 Mass Spectrometry 
The purity of protein preparation was analyzed using MALDI-ToF mass 
spectrometry (Bruker Daltonics Inc). The sinnapinic acid (SA) matrix was prepared by 
resuspending 10 mg of SA (Sigma) in one mL of 1:1 acetonitrile: water with 0.1% TFA. 
One μL of protein samples was mixed with one μL of SA matrix such that the final 
protein concentration was in 0.01 – 0.1 nM range. Protein-matrix mixture was then 
spotted in duplicates (1 μL) on a MSP 96 microchip target (Bruker). The laser intensity 
and the detector gain were kept constant at 70-90% laser and 3x detector gain. For 
alkylation experiments, 2-4 μg of GRN-3, mGRN-3, or rGRN-3 was incubated with 
2000x molar excess of iodoacetamide solution in presence of 1000x molar excess of 
guanidium hydrochloride at room temperature for 90 mins to overnight in dark. The 
 79 
alkylation of rGRN-3 or lack of thereof in GRN-3 or mGRN-3 was assessed using 
MALDI-ToF. 
5.2.9 Fluorescence Spectroscopy 
Fluorescence measurements were performed on a Cary Eclipse spectrometer 
(Agilent Inc.). Emission spectral scans between 320-400 nm arising from intrinsic 
tryptophan fluorescence were measured by exciting the samples at 280 nm. The 
excitation and emission slits were set at 10 or 20 nm.  For ANS binding assay of rGRN-3, 
the concentration of ANS was kept constant at 500 μM as the rGRN-3 was diluted from 
25 μM to 1 μM. Scans were obtained by exciting the samples at 380 nm and reading the 
emission between from 410 and 600 nm with excitation and emission slits set at 10 nm 
each. For both tryptophan and ANS experiments, an average of three scans were 
collected. The data obtained was fit to the following equation for a monomer-dimer 
model using Origin 8.5 software. 
𝐹 =
2
𝑀
∗ {𝐹0 − (𝐹0 − 𝐹𝑓 ) ∗ (
(4𝑀 +  𝐾𝑑) ± √(4𝑀 +  𝐾𝑑)2 − 16𝑀2 
8
)} 
in which F is the fraction dimer, M is the monomer concentration, F0 is initial 
dimer fraction, Ff is the final dimer fraction, and Kd is the dissociation equilibrium 
constant. For ANS binding of GRN-3 or mGRN-3, 25 μM of either was incubated with 
500 μM ANS as scans were obtained as detailed above. An average of 9 scans were 
collected to reduce the signal to noise ratio. For Stern-Volmer analysis, 10 & 100 μM of 
rGRN-3 and 25 μM of GRN-3 or mGRN-3 were titrated with acrylamide ranging from 
0.1 to 3 M and the tryptophan fluorescence was monitored as detailed above. Tryptophan 
fluorescence without the quencher was also obtained by appropriately diluting the protein 
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using buffer. The F0/F (without quencher/with quencher) was plotted against the 
quencher concentration using the Origin 8.5 software to obtain the Stern-Volmer plot. 
For TMR-Aβ42-GRN-3 binding experiments, the experimental procedure has 
been described in section 3.2.1. For ThT fluorescence, the samples were diluted 15-fold 
using 10 μM ThT prepared in 20 mM Tris, pH 8.0 or 6.5. Continuous measurements of F 
were taken for 1 minute with the excitation and emission wavelengths fixed at 450 and 
482 nm respectively, and the excitation and emission slits set at 10 nm. 
5.2.10 Circular Dichroism (CD) 
Far-UV CD spectra were obtained on a Jasco J-815 CD spectrometer. For protein 
samples with concentration up to 100 μM, a 1 mm path length quartz cuvette (Hellma) 
was used, whereas, for concentrations above 200 μM, 0.1 mm path length quartz cuvette 
(Precision cell) was used. Similarly, for effect of TMAO on GRN-3 structure, 0.1 mm 
path length quartz cuvette (Precision Cell) was used to minimize the scattering. The 
samples were monitored in a continuous scan mode from 260 to 198 nm with a scanning 
speed of 50 nm/min with a data integration time of 8 s, 1 nm bandwidth, and the data 
pitch of 0.1 nm. Each data set was an average of 3 scans and appropriate blanks were 
subtracted as indicated in the results sections. The corrected scans were smoothened 
using the Savitzky-Golay algorithm (provided by the manufacturer) with the convolution 
width of 15 using the Jasco spectrum analysis program. For temperature melt 
experiments, the samples were first scanned at 25 °C, prior to addition of 1 % SDS, using 
the continuous scan mode from 260 to 195 nm with a scanning speed of 50 nm min-1 with 
a data integration time of 8 seconds, 1 nm bandwidth, and a data pitch of 0.1 nm. Each 
data set represents an average of 3 scans with appropriate blank subtraction. After adding 
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SDS, the samples were scanned immediately over the temperature range of 10 °C to 90 
°C with an interval of 10 °C and a ramp rate of 10 °C/min using the temperature interval 
scan method. Rest of the parameters were same as continuous scanning mode. The scans 
were subjected to smoothening via the Savitzky-Golay algorithm (provided by the 
manufacturer) with the convolution width of 9 using the Jasco spectrum analysis 
program, were blank subtracted, zero corrected, and normalized using Origin 8.5. 
5.2.11 Analytical Ultracentrifugation (AUC) 
AUC experiments were performed in a Beckman XL-I centrifuge (Beckman 
Coulter, Inc., Indianapolis, IN) using absorbance optics by measuring intensity scans at 
280 nm by Dr. Claudius Mundoma at the Institute of Molecular Biophysics, Florida State 
University. The experiments were performed at 20 °C in two-channel Epon centerpieces 
with an AN60 Ti rotor at 55,000 rpm. The protein was solubilized using the buffer 20 
mM Tris pH 6.5 protein. Data were analyzed using the UltraScan III version 3.3 software 
suite.197. Data were first analyzed with the two-dimensional spectrum analysis with 
simultaneous time-invariant noise subtraction according to the method of Schuck and 
Demeler.198 After noise subtraction, the data were examined for heterogeneity with the 
enhanced van Holde−Weischet analysis.199 The partial specific volume at 20 °C of the 
GRN-3 protein (0.7021cm3/g) was estimated from the peptide sequence as described by 
Durchschlag.200 All the raw data were processed using SEDFIT program (3) to generate 
c(s) distributions. A constant diffusion coefficient for all samples was assumed and an 
f/f0 value of 1.4. 
 
 82 
5.2.12 SOFAST Heteronuclear Multiple Quantum Coherence (HMQC) NMR 
Spectroscopy 
The NMR spectra for GRN-3, mGRN-3, or rGRN-3 was acquired on the Bruker 
Advance – III-HD 850 MHz NMR spectrometer equipped with a Bruker TCI cryoprobe 
at the high field NMR facility of University of Alabama, Birmingham. SOFAST HMQC 
was used as it allows reduction of the recycle delays (Tscan) to ≤ 100 ms while 
maintaining high sensitivity thereby decreasing the overall experimental time.201 HMQC 
spectra was obtained for 40 μM (152 μg) of GRN-3 or mGRN-3 and 10 μM (38 μg) of 
rGRN-3 resuspended in 20 mM Tris, pH 6.5 with 10% D2O inside a Shigemi NMR tube. 
The spectra were collected with 2048 data points in F2 (1H) with 128 scans coadded for 
each of the 160 F1 (15N) increments. A 1J(NH) of 90 Hz was used with a 100 ms relaxation 
delay. The delay interval from F1 to F2 was set at 0.32 ms. The spectra was acquired at 
25 °C. The HMQC spectra were processed using Bruker TopSpin 3.5 analysis software 
with standard methods with phase corrections in both dimensions. 
5.2.13 Human Neuroblastoma SH-SY5Y Cell Culture and Treatment 
The cell culture and treatment was carried out by Lauren Wolf from Dr. Melissa 
Moss’s group at the University of South Carolina. Human neuroblastoma SH-SY5Y cells 
(Sigma-Aldrich) were maintained in a 1:1 mixture of DMEM and Ham’s F12K medium 
supplemented with FBS (10%), penicillin (100 Units mL-1), and streptomycin (100 μg 
mL-1). All cultures were maintained at 37 °C in a humid atmosphere of 5% CO2 and 95% 
air. SH-SY5Y cells were seeded onto 22 x 22 mm glass coverslips (Corning) at a density 
of 4 × 105 cells mL-1 and allowed to stabilize in culture for 24 hours. Cells were then 
treated for 60 minutes at 37 C with rGRN-3 diluted into cell culture medium containing 
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1% FBS to achieve final concentrations of 0.02-2 M rGRN-3. Parallel treatment with an 
equivalent dilution of buffer (20 mM Tris-HCl, pH 6.5, 50 mM NaCl) served as the 
negative control. Cells were fixed and assessed via immunocytochemistry for normalized 
cellular NF-B activation and results are reported as the mean  SEM for 3-4 
independent trials. Statistical analysis was performed with a one-way ANOVA using 
GraphPad Prism 6 software. When the results of the ANOVA analysis demonstrated 
significance, a Dunnett’s test for multiple comparisons identified groups with means 
significantly different than the control. 
5.2.14 Immunocytochemistry 
Following 60 minutes rGRN-3, GRN-3, or mGRN-3 treatment, cells were washed 
with medium containing 1% FBS and fixed with 4% paraformaldehyde in PBS for 10 
minutes at 25 C. Fixed cells were rinsed 3x with DPBS, permeabilized (0.1% Triton 
X-100, 0.01 mol L-1 glycine in DPBS), and rinsed again with DPBS. To prevent non-
specific binding, cells were blocked first with 5% BSA in DPBS, followed by 5% normal 
donkey serum, 1% BSA in DPBS. Cells were incubated overnight at 4 C with the 
primary antibody MAB3026 (Millipore), which is specific for the activated form of the 
NF-B p65 subunit, diluted 1:1200 in DPBS. Labeled cells were rinsed with 1% BSA in 
DPBS prior to blocking with 5% normal donkey serum, 1% BSA in DPBS. Bound 
primary antibody was detected via incubation for 2 hours at 25 C with Alexa Fluor 555 
conjugate goat anti-mouse secondary antibody diluted 1:1000 in DPBS. After rinsing 3x 
with 1% BSA in DPBS followed by 2x with DPBS prepared coverslips were mounted 
onto slides using Fluoroshield with DAPI (Sigma-Aldrich). 
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Slides were visualized under a Zeiss LSM 510 META Confocal Scanning Laser 
Microscope (Carl Zeiss) using a plan-neofluar 40X/1.3 oil DIC immersion objective (Carl 
Zeiss). Z-stacks of the two-channels, corresponding to fluorescently-labeled activated 
NF-B and DAPI-labeled nuclei, were acquired to encompass the entire cell layer; z-
stacks of three different fields were captured for each treatment.202, 203 was used to create 
a z-projection of maximum intensity for each of the two channels within every acquired 
z-stack. The resultant two-channel images were converted to TIFF files for quantitative 
image analysis using a custom subroutine written in Matlab™ software (MathWorks). 
Here, images were separated into the two channels, and each channel was converted into 
8-bit monochrome images. DAPI images were transformed into 8-bit binary images via 
comparison of individual pixel values to a common threshold, and noise was removed. 
Nuclei were then identified by tagging the pixels representative of nuclear boundaries and 
identifying successive ‘layers’ of pixels toward the interior of this boundary until 
convergence was reached. Upon convergence, a cell was counted, and a radius of 
exclusivity was defined within which another cell could not be identified. Next, 8-bit 
monochrome NF-B images were used to calculate the fluorescence associated with 
activated NF-B, which was divided by the number of cells to yield the activated NF-B 
fluorescence per cell. This cellular NF-B activation was determined using the three 
images acquired for each treatment. Reported values are normalized to the cellular NF-
B activation observed for the control. 
5.2.15 I-TASSER Analysis 
The structure prediction of GRN-3 was carried out using the free structure 
predicting tool called I-TASSER (Iterative Threading ASSEmbly Refinement) available 
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at http://zhanglab.ccmb.med.umich.edu/I-TASSER/. The primary amino acid sequence of 
GRN-3 was submitted in the FASTA format. Briefly, I-TASSER identifies similar 
structural templates from PDB (protein data bank) using multiple threading approach 
LOMETS (local meta-threading server). The server then uses the iterative template 
fragment assembly simulations to generate the full-length atomic models. Each predicted 
model is assigned a c-score or the confidence score which determines the validity of the 
prediction; higher the c-score, higher the validity of prediction. 
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